A novel genome editing system based on C2C9 nuclease and uses thereof
The C2C9 nuclease-based CRISPR/C2C9 system addresses the size limitations of CRISPR/Cas9 and CRISPR/Cas12a by enabling efficient and precise genome editing, enhancing delivery and targeting in various biological applications.
Patent Information
- Application Number
- JP2024531724
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-30
- Filing Date
- 2022-11-17
- Publication Date
- 2024-11-19
AI Technical Summary
Current CRISPR/Cas genome editing systems, such as CRISPR/Cas9 and CRISPR/Cas12a, face challenges due to the large size of their effector proteins, which limits packaging efficiency in lentiviral vectors and restricts genomic targeting sites, hindering applications in fields like gene therapy and biology.
A novel CRISPR/C2C9 genome editing system utilizing a smaller C2C9 nuclease, which forms a complex with guide RNA to accurately target and cleave genomic DNA, overcoming size limitations and expanding targeting possibilities.
The C2C9 nuclease enables efficient and precise genome editing in prokaryotic and eukaryotic cells, facilitating applications in biotechnology, medicine, and agriculture by improving delivery and targeting capabilities.
Smart Images

Figure 2024543186000001 
Figure 2024543186000002 
Figure 2024543186000003
Abstract
Description
[Technical field]
[0001] The present invention belongs to the field of biomedicine and relates to a novel genome editing system based on the ultrasmall C2C9 nuclease, and the method and use of said system for genome editing in prokaryotic bacteria and eukaryotic cells. [Background technology]
[0002] CRISPR / Cas (Clustered regularly interspaced short palindromic repeats / CRISPR-associated protein) is a novel gene editing system developed in recent years. The system is mainly composed of Cas endonuclease and corresponding guide RNA. Cas endonuclease specifically binds to the guide RNA, recognizes and cuts a specific site of the genome as a target through complementary base pairing, and breaks the double strand of genomic DNA. Then, the broken genomic DNA is repaired by the endogenous or exogenous DNA repair mechanism of the organism, such as the repair mechanism of end-joining homologous recombination and non-homologous recombination, thereby realizing editing of a specific site of the genome during the repair process.
[0003] Genetic manipulation of cells or seeds using the CRISPR / Cas system can be widely applied in basic research, development of biological technology, and research and development of disease treatment methods in the fields of life science, medicine, agriculture, etc. For example, it can be used to correct mutated genes of diseases such as genetic diseases and cancer, genetic engineering modification of agricultural crops to improve their performance, precisely modify the genome of microorganisms to promote the production of high-value-added compounds, and cut the genome of pathogenic microorganisms to kill them and treat infections. Due to the convenience and efficiency of the CRISPR / Cas system, it has already been widely applied in the fields of medicine, biology, agriculture, etc.
[0004] At present, the widely used CRISPR / Cas genome editing systems mainly include two types: CRISPR / Cas9 and CRISPR / Cas12a. In these two genome editing systems, the CRISPR effector proteins, nuclease Cas9 and Cas12a, are both large proteins containing more than 1000 amino acids, so there are major problems in the process of delivering CRISPR / Cas9 or CRISPR / Cas12a to cells. For example, in the process of gene therapy in living organisms, the CRISPR / Cas9 or CRISPR / Cas12a system always needs to be packaged into a lentiviral vector for use. However, due to the limited packaging capacity of lentiviral vectors, the large molecular size of the CRISPR / Cas9 and CRISPR / Cas12a systems limits the packaging efficiency of lentiviral vectors, increasing the difficulty of packaging, which greatly restricts the wide application of these systems in fields such as gene therapy. In addition, the limited number of protospacer adjacent motifs (PAMs, PAM sequences or PAM sites) recognized by the CRISPR / Cas system restricts the sites of genome that can be selected, affecting further applications in fields such as medicine and biology. Therefore, there is a strong need to discover and develop novel genome editing systems that are efficient and small in molecular weight. Summary of the Invention
[0005] The present invention provides a miniaturized genome editing system (including the CRISPR / C2C9 system) and method. The genome editing system of the present invention can achieve precise gene knockout or editing by precise cleavage at target sites in prokaryotic bacteria and eukaryotic cells. The present invention also provides a novel RNA-editing endonuclease. The invention further relates to guide RNAs (gRNAs) and / or other components comprising targeting sequences, and methods of producing and using them in various applications. Examples of such applications include methods for regulating transcription, and methods for targeting, editing and / or manipulating genes (e.g., DNA and RNA) with novel nucleases and other components, e.g., nucleic acids and / or polypeptides. The invention further relates to recombinant cells and kits, etc., that contain elements of the editing system.
[0006] In one aspect of the present invention, there is provided a genome editing system for performing gene editing on at least one target sequence in a genome, the genome editing system comprising: (a) a C2C9 nuclease or a nucleic acid encoding a C2C9 nuclease, and (b) a guide RNA (gRNA) or a nucleic acid encoding said gRNA.
[0007] The C2C9 nuclease forms a complex with its matching guide RNA.
[0008] In one preferred embodiment, the genome editing system is a CRISPR-C2C9 genome editing system.
[0009] In one preferred embodiment, the CRISPR-C2C9 genome editing system comprises: (1) an expression construct for C2C9 nuclease; (2) an expression construct for the complete guide RNA; The complete guide RNA comprises a guide RNA backbone and an RNA sequence corresponding to a target sequence added to the 3' end of the guide RNA backbone, the target sequence being a nucleic acid fragment having a length of 12-40 bp after the PAM sequence, preferably a nucleic acid fragment having a length of 20 bp after the PAM sequence. The C2C9 nuclease according to the present invention may be a conventional C2C9 nuclease in the art. Advantageously, the size of the C2C9 nuclease is preferably 800 amino acids or less. More preferably, the C2C9 nuclease is derived from any one of the following amino acid sequences or SEQ ID NOs: 3-117 having at least 80% sequence homology with any one of the following amino acid sequences: In one embodiment, the C2C9 nuclease is selected from the group consisting of Actinomadura craniellae C2C9 (AcC2C9), Corynebacterium glutamicum C2C9 (CgC2C9), Rothia dentocariosa C2C9 (RdC2C9) and Micrococcus luteus C2C9 (MilC2C9), etc.
[0010] In a preferred embodiment of the present invention, the C2C9 nuclease is AcC2C9 nuclease as shown in SEQ ID NO: 3 in the sequence listing.
[0011] In one embodiment, the nucleic acid encoding the AcC2C9 nuclease is a deoxyribonucleic acid (DNA). In one embodiment, the DNA coding sequence of the AcC2C9 nuclease is set forth in SEQ ID NO: 121 in the sequence listing, or a variant having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO: 121.
[0012] In one embodiment, the nucleic acid encoding the AcC2C9 nuclease is ribonucleic acid (RNA). In one embodiment, the RNA encoding the AcC2C9 nuclease is It is mRNA.
[0013] In one embodiment, the sequence encoding the AcC2C9 nuclease is a coding sequence optimized according to human codons, preferably as shown in SEQ ID NO: 122 in the sequence listing, or a variant having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 122.
[0014] In some embodiments, the C2C9 nuclease or a nucleic acid encoding the C2C9 nuclease is formulated in a liposome or lipid nanoparticle. In some embodiments, the liposome or lipid nanoparticle also comprises the gRNA or a nucleic acid encoding the gRNA.
[0015] In one embodiment, the system includes a C2C9 nuclease pre-coordinated with a gRNA to form a ribonucleoprotein (RNP) complex that recognizes a PAM sequence in a target gene (e.g., a target DNA) sequence, i.e., precisely localized next to the DNA sequence, where the complex of C2C9 nuclease and guide RNA recognizes the PAM sequence in the target gene.
[0016] Here, the backbone sequence of the guide RNA of the AcC2C9 nuclease is shown in sequence number 120 in the sequence listing.
[0017] In one embodiment, the complete guide RNA expression construct comprises an expressed DNA sequence of a guide RNA backbone and an expressed DNA sequence of an RNA sequence corresponding to a target sequence appended to the 3' end of the expressed DNA sequence, where the target sequence is a 20 bp long fragment following a PAM sequence.
[0018] Here, the PAM site preferably recognized by the CRISPR-C2C9 genome editing system is AAN and / or GAN.
[0019] In some embodiments, the system according to the present invention may further comprise a donor template containing a foreign polynucleotide sequence, wherein the foreign polynucleotide sequence can be inserted into the target polynucleotide sequence. In some embodiments, the donor template of the foreign polynucleotide is physically linked to the gRNA.
[0020] In another aspect, the invention provides a method for targeting, editing, modifying or manipulating double-stranded DNA at a target locus, comprising mixing a C2C9 nuclease, a complete guide RNA and said double-stranded DNA in a system as described above, said complete guide RNA being 5'-guide RNA backbone corresponding to said C2C9 nuclease+RNA sequence corresponding to a target sequence in said double-stranded DNA-3'. In one embodiment, said method is used to cleave double-stranded DNA.
[0021] In some embodiments, the present invention provides a method of targeting, editing, modifying or manipulating double-stranded DNA at a target locus in a cell as described above, in some embodiments, the method further comprises introducing a polynucleotide donor template into the cell, wherein the donor template is a donor single-stranded or double-stranded polynucleotide donor template.
[0022] In certain embodiments of the invention, DNA is repaired in the DBS by homology directed repair, non-homologous end joining, or microhomology-mediated end joining.
[0023] As mentioned above, the backbone of a suitable guide RNA corresponding to the AcC2C9 nuclease is shown in the sequence listing as SEQ ID NO: 120. Adding target RNA sequences for different target sequences to its 3' end results in a complete guide RNA.
[0024] The preferred limitations for the C2C9 nuclease are as described above, and are preferably derived from the group consisting of SEQ ID NOs: 3 to 117, and more preferably from Actinomadura craniellae C2C9 (AcC2C9), Corynebacterium glutamicum C2C9 (CgC2C9), Rothia dentocariosa C2C9 (RdC2C9) and Micrococcus luteus C2C9 (MiC2C9), more preferably as shown in SEQ ID NO: 3 or a variant thereof in the sequence listing. A more preferred coding sequence optimized according to human codons for the AcC2C9 nuclease is shown in SEQ ID NO: 122 in the sequence listing. The variant has at least 20% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence homology with the amino acid residues of SEQ ID NO: 3, and retains RNA-guided DNA binding activity and / or double-stranded DNA cleavage activity.
[0025] The cleavage method according to the present invention may be any method known in the art, for example, in a preferred embodiment of the present invention, the cleavage method is carried out under conditions of 50-200 mM NaCl and / or 5-20 mM MgCl2. For example, the NaCl concentration is 50-100 mM, 100-150 mM, or 150-200 mM. For example, the MgCl2 concentration is 5-10 mM, 10-15 mM, or 15-20 mM. It is preferably carried out in a buffer solution of 150 mM NaCl, 10 mM MgCl2, 10 mM Tris-HCl, pH=7.5, and 1 mM DTT.
[0026] In the above cleavage method, the reaction temperature is 34 to 43° C., for example, 34 to 37° C., 37 to 40° C., or 40 to 43° C., preferably 37° C., and the reaction time is preferably 30 to 60 minutes.
[0027] In another aspect, there is provided a genome editing method comprising introducing the aforementioned genome editing system into a prokaryotic bacterium or eukaryotic cell containing a target sequence to perform genome editing.
[0028] Prokaryotic bacteria according to the present invention include, but are not limited to, prokaryotic microorganisms such as Escherichia coli and Klebsiella pneumoniae.
[0029] Eukaryotic cells according to the present invention include, but are not limited to, eukaryotic cells such as mammalian cells, yeast, and the like.
[0030] The "gene editing" in the above-mentioned genome editing method may be any of the conventional methods in the field, such as gene cleavage, gene deletion, gene insertion, point mutation, transcriptional repression, transcriptional activation, base editing, and guided editing, but is not limited to these.
[0031] In another aspect, the present invention provides the use of C2C9 nuclease in genome editing.
[0032] Further limitations to the C2C9 nuclease and the gene editing are as described above. do.
[0033] The size of the nuclease in this genome editing system is less than 800 amino acids.
[0034] In another aspect, the present invention provides a modified cell, the genome of which has been edited by any one of the aforementioned systems or methods. In one embodiment, the modified cell comprises (a) the aforementioned C2C9 nuclease or a nucleic acid encoding the C2C9 nuclease, and (b) a guide RNA (gRNA) or a nucleic acid encoding the gRNA, wherein the gRNA can guide the C2C9 nuclease or a variant thereof to a target polynucleotide sequence. In one embodiment, the modified cell further comprises a donor template containing a foreign polynucleotide sequence, wherein the foreign polynucleotide sequence can be inserted into the target polynucleotide sequence.
[0035] The positive advantages of the present invention include: CRISPR / C2C9 is a novel genome editing system discovered by the applicant, which includes C2C9 nuclease and gRNA, and the system is small in size (C2C9 nuclease is generally 800 amino acids or less) and does not require complex PAM (the PAM site it recognizes is AAN, etc.). With the complete guide and localization function of the guide RNA, C2C9 nuclease can accurately localize, target, cleave genomic DNA in the body, in vitro cellular or acellular environment, and realize double-strand breaks in genomic DNA. By utilizing the host cell's own or foreign repair mechanism, the system can efficiently and accurately realize genome editing in the body or in vitro cellular or acellular environment. [Brief description of the drawings]
[0036] [Figure 1]This is a diagram of the flow and results of the identification of PAM for AcC2C9. The results showed that AcC2C9 can efficiently recognize 5'-AAN type PAM sequences and a small amount of 5'-GAN sequences (where N is a degenerate base, representing any one of A, T, C or G). Here, the horizontal coordinates -1, -2, -3, -4, -5, and -6 represent the 1st, 2nd, 3rd, 4th, 5th, and 6th DNA bases located upstream of the 5' end of the sequence of the target DNA region in the NTS strand (non-target strand), respectively. The alphabets above them represent the preference of AcC2C9 nuclease for the DNA sequence, and the higher the ratio of the alphabet, the stronger the preference of AcC2C9 for the base. [Diagram 2] Figure 1 shows the results of PAM identification for CgC2C9, RdC2C9 and MiC2C9. The results showed that CgC2C9 can efficiently recognize 5'-AAS type PAM sequences (where S is a degenerate base and C represents either one of the bases A or G), and RdC2C9(B) and MiC2C9(C) can efficiently recognize 5'-AAN type PAM sequences (where N is a degenerate base and A, T, or C represents either one of the bases). [Diagram 3] Figure 1 shows the PCR results of gene knockout in living cells of Klebsiella pneumoniae by the CRISPR-AcC2C9 system. The results showed that the selected dha gene could be precisely knocked out by the CRISPR-AcC2C9 system. [Figure 4] Figure 1 shows the results of cleaving the substrate DNA with AcC2C9 nuclease. The results showed that the substrate DNA was precisely cleaved into two DNA fragments by AcC2C9. [Diagram 5] Figure 1 shows the reaction activity of AcC2C9 nuclease at different temperatures (A), different NaCl concentrations (B), different MgCl2 concentrations (C), and different divalent ions (D). The results showed that AcC2C9 was most active at 40°C, 100 mM NaCl, and 10 mM MgCl2. [Figure 6](A) is a schematic diagram of the complete guide RNA sequence of AcC2C9, and (B) is a diagram showing the cleavage of substrate DNA by AcC2C9 nuclease under tracrRNA and crRNA conditions. [Figure 7] Cleavage of four 58-bp fluorescently labeled DNA substrates by AcC2C9 nuclease. The results showed that the main cleavage site of AcC2C9 on the target strand was 21-22 nt downstream of the 3' end of the PAM site, and the main cleavage site on the non-target strand was 15-16 nt downstream of the 3' end of the PAM site. [Figure 8] Figure 1 shows the results of gene editing in human cells mediated by AcC2C9 transient expression plasmid. (A) is a TBE-PAGE gel of the Indel experiment. Among the five different gene sites selected, AcC2C9 nuclease successfully achieved efficient gene editing in three genes, VEGFA, HEXA and DNMT1. (B) is a statistical result of high-throughput sequencing after editing of VEGFA gene in human cells mediated by AcC2C9 transient expression plasmid. As shown in the figure, AcC2C9 nuclease could precisely introduce insertion or deletion mutations into the target sequence. [Figure 9] FIG. 13 shows the efficiency of gene editing at 47 sites in HEK293T cells with AcC2C9 transient expression plasmid. [Figure 10] FIG. 11 shows the editing efficiency of AAV expressing the AcC2C9 system at three different gene sites in human cells HEK293T, HLEA, U-2OS, Huh-7 and HepG cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0037] The present invention will be further described below by combining specific examples. It is understood that these examples are only used to explain the present invention and do not limit the scope of the present invention. In addition, after reading the contents of the present invention, a person skilled in the art can make various variations and modifications to the present invention, and it should be understood that the equivalent embodiments are also included in the scope of the claims of the present invention.
[0038] The terms "C2C9," "C2C9 nuclease," "C2C9 polypeptide," "C2C9 protein," and "C2C9 protein" can be used interchangeably.
[0039] The terms "guide RNA," "gRNA," "single gRNA," and "chimeric gRNA" can be used interchangeably.
[0040] It should be noted that, as used herein, the term "a" or "one" entity refers to one or more such entities, and therefore the terms "a" (or "one"), "one or more," and "at least one" can be used interchangeably herein.
[0041] The terms "homology" or "identity" or "similarity" refer to the similarity of sequences between two peptides or between two nucleic acid molecules. Homology can be determined by comparing corresponding positions in different peptides or nucleic acid molecules; if an identical position in the sequences of the compared molecules is occupied by a similar base or amino acid in the different sequences, then the molecules are homologous at that position. The degree of homology between sequences is determined as a function of the number of matching or homologous positions that the sequences share. An "unrelated" or "non-homologous" sequence should have less than 20% homology with one of the sequences disclosed in this invention.
[0042] A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) may be bound to another polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) at a given percentage (e.g., 20%, 30%, 40%, 50%, %, 60%, 70%, 80%, 90%, 95%, 98% or 99% sequence homology means that the percentage of bases (or amino acids) in the two aligned sequences are similar. The alignment and percentage homology or sequence identity can be determined by software and methods known in the art, for example, as described in Ausubel et al. eds. (2007) Current Protocols in Molecular Biology. Preferably, for sequence alignment, default parameters are used. Among them, one of the alignment programs to choose from is BLAST, with default parameters used. In particular, when performing alignments with the programs BLASTN and BLASTP, the following default parameters are used: Genetic code=standard; filter=none; strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50 sequences; sort by=HIGH SCORE; Databases=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translations+SwissProtein+SPupdate+PIR. Polynucleotides that are considered to be equivalent in biological terms are polynucleotides that have the percentage homology defined above and encode polypeptides that have the same or similar biological activity.
[0043] When the polynucleotide is DNA, the sequence of the polynucleotide consists of an alphabet representing the four nucleotide bases adenine (A), cytosine (C), guanine (G) and thymine (T). When the polynucleotide is RNA, the sequence of the polynucleotide consists of an alphabet representing the four nucleotide bases adenine (A), cytosine (C), guanine (G) and uracil (U). Thus, the term "polynucleotide sequence" refers to the alphabet representation of the polynucleotide molecule. The alphabet representation can be entered into a database in a computer having a central processing unit and used in bioinformatics applications, such as functional genomics and homology searches. The term "polymorphism" refers to the coexistence of more than one form of a gene or part thereof, and a "polymorphic region of a gene" refers to a gene having different forms of nucleotide expression (i.e., different nucleotide sequences) at the same position. A polymorphic region of a gene can be a single nucleotide, which differs in different alleles.
[0044] In the present invention, the terms "polynucleotide" and "oligonucleotide" are used interchangeably and refer to a polymerized form of nucleotides of any length, which may be deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure and may perform any function, known or unknown. Examples of polynucleotides include, but are not limited to, genes or gene fragments (including probes, primers, EST or SAGE tags), exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, dsRNA, siRNA, miRNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. Polynucleotides also include modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present in a polynucleotide, the modification may be imparted before or after assembly of the polynucleotide. The nucleotide sequence may be interrupted by non-nucleotide moieties. Polynucleotides may be further modified after polymerization and labeled, for example, by coupling with a labeling moiety. The term simultaneously refers to double-stranded and single-stranded polynucleotide molecules. Unless otherwise stated or required, any embodiment of a polynucleotide disclosed in the present invention includes its double-stranded form and any of the two complementary single-stranded forms that are known or can be expected to constitute a double-stranded form.
[0045] The term "code," when applied to a polynucleotide, means that the polynucleotide "encodes" a polypeptide, such that, in its natural state, or when manipulated by methods known to those of skill in the art, it is capable of producing a target polypeptide and / or fragments thereof by transcription and / or translation, or of producing mRNA that encodes the target polypeptide and / or fragments thereof. The antisense strand is a sequence complementary to the polynucleotide from which the coding sequence can be deduced.
[0046] The term "genomic DNA" refers to DNA from the genome of an organism, and includes DNA from the genome of a bacterium, archaea, fungus, protist, virus, plant or animal.
[0047] The term "manipulating" DNA includes binding, making a cut in a single strand or breaking a double strand of DNA, or modifying or editing the DNA or a polypeptide bound to the DNA. Manipulating DNA can silence, activate or modulate (prevent transcription or reduce transcriptional activity or prevent translation or reduce the level of translation) the expression of an RNA or polypeptide encoded by said DNA, or prevent or enhance binding of the polypeptide to the DNA. Cleavage can be achieved in many ways, for example, by enzyme-catalyzed or chemical hydrolysis of phosphodiester bonds, and can be a single-strand or double-strand break, with DNA cleavage leading to the generation of blunt or overhanging ends.
[0048] The terms "hybridizable" or "complementary" or "essentially complementary" refer to a nucleic acid (e.g., RNA) that contains a nucleotide sequence that allows it to non-covalently bind, i.e., form Watson-Crick base pairs and / or G / U base pairs, "anneal" or "hybridize" to another nucleic acid in a sequence-specific, antiparallel manner under appropriate in vitro and / or in vivo conditions of temperature and solution ionic strength.
[0049] It is understood in the art that the sequence of a polynucleotide does not need to be 100% complementary to the sequence of the target nucleic acid to which it can specifically hybridize. A polynucleotide may hybridize in one or more regions. A polynucleotide may have at least 70%, at least 80%, at least 90%, at least 95%, at least 99% or 100% sequence complementarity with the target region in the target nucleic acid sequence to which it targets. The percentage complementarity between specific nucleic acid sequence regions in nucleic acids can be determined routinely by known BLAST and PowerBLAST programs in the art.
[0050] As used herein, the terms "peptide", "polypeptide" and "protein" are used interchangeably to refer to polymeric forms of amino acids of any length, and may include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones.
[0051] The term "binding domain" refers to a protein domain that can bind non-covalently to another molecule. A binding domain may, for example, bind to a DNA molecule (a DNA-binding protein), an RNA molecule (an RNA-binding protein) and / or a protein molecule (a protein-binding protein). In the case of a protein domain-binding protein, it may bind to itself (to form a homodimer, homotrimer, etc.) and / or to one or more molecules of one or more different proteins.
[0052] The term "conservative amino acid substitution" refers to the interchangeability of amino acid residues having similar side chains in a protein. An exemplary set of conservative amino acid substitutions is valine-leucine-isoleucine. , phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.
[0053] The term DNA sequence "encoding" a particular RNA is a DNA nucleic acid sequence that is transcribed into RNA. A DNA polypeptide may encode an RNA (mRNA) that is translated into a protein, or a DNA polypeptide may encode an RNA that is not translated into a protein (e.g., tRNA, rRNA, or gRNA, also called "non-coding" RNA or "ncRNA"). A "protein coding sequence" or a sequence that encodes a particular protein or polypeptide is a nucleic acid sequence that is transcribed into mRNA (in the case of DNA) and translated into a polypeptide (in the case of mRNA) in vivo or in vitro, under the control of appropriate regulatory sequences.
[0054] The term "vector" or "expression vector" refers to a replicon, such as a plasmid, phage, virus, or cosmid, to which another DNA segment, or "insert," can be attached so as to bring about the replication of the added segment in a cell.
[0055] The term "expression cassette" includes a DNA coding sequence operably linked to a promoter. "Operably linked" refers to a juxtaposition in which the components are in a relationship that allows them to function in their expected manner. In the present invention, the terms "recombinant expression vector" or "DNA construct" are used interchangeably and refer to a DNA molecule that includes a vector and at least one insert. Recombinant expression vectors are typically generated for the purposes of expressing and / or amplifying an insert or constructing other recombinant nucleotide sequences.
[0056] When foreign DNA, e.g., a recombinant expression vector, has already been introduced into a cell, the cell has already been "genetically modified" or "transformed" or "transfected" with said DNA. The presence of the foreign DNA can result in a permanent or temporary genetic alteration. The transforming DNA may or may not be integrated into the genome of the cell.
[0057] The term "target DNA" is a DNA polynucleotide that contains a "target site" or "target sequence." In the present invention, the terms "target site," "target sequence," "target protospacer DNA," or "protospacer-like sequence" are used interchangeably and refer to a nucleic acid sequence present in the target DNA to which the DNA-targeting region of the gRNA binds when sufficient binding conditions exist. The RNA molecule contains a sequence that binds, hybridizes, or is complementary to the target sequence in the target DNA, thereby targeting the bound polypeptide to a specific location (target sequence) in the target DNA. "Cleavage" is the breakage of the covalent backbone of a DNA molecule.
[0058] The terms "nuclease" and "endonuclease" can be used interchangeably and refer to an endonucleasing nucleolytic catalytic activity for cleaving polynucleotides. A "cleavage domain" or "active domain" or "nuclease domain" of a nuclease is a polypeptide sequence or domain that has catalytic activity for DNA cleavage in a nuclease. A cleavage domain may be contained in a single polypeptide chain, or the cleavage activity may occur through the binding of two or more polypeptides.
[0059] The term "localization polypeptide" or "RNA-binding site guide polypeptide" is a polypeptide that targets RNA binding to a specific DNA sequence.
[0060] The term "guide sequence" or DNA-target region (or "DNA-target sequence") comprises a nucleotide sequence that is complementary to a specific sequence in the target DNA (the complementary strand of the target DNA), which is referred to in the present invention as a "protospacer-like" sequence.
[0061] The term "recombination" refers to the process of exchanging genetic information between two polynucleotides. As used herein, "homologous recombination repair (HDR)" refers to a specialized form of DNA repair that occurs, for example, during the repair of double-stranded breaks in cells. This process requires nucleotide sequence homology and uses a "donor" molecule as a template to repair a "target" molecule (i.e., the molecule that has undergone the double-stranded break), such that genetic information is transferred from the donor to the target. If the donor polynucleotide is different from the target molecule and some or all of the sequence of the donor polynucleotide is incorporated into the target DNA, homologous recombination repair can lead to alterations (e.g., insertions, deletions, mutations) in the sequence of the target molecule.
[0062] The term "non-homologous end joining (NHEJ)" refers to the repair of double-strand breaks in DNA by direct joining of the broken ends without the need for a homologous template. NHEJ often leads to the deletion of nucleotide sequences near the site of the double-strand break.
[0063] The term "treatment" includes preventing the occurrence of a disease or condition, inhibiting a disease or condition, or relieving a disease.
[0064] As used herein, the terms "individual," "subject," "host," and "patient" are used interchangeably and refer to any mammalian subject, particularly humans, for whom diagnosis, treatment, or therapy is desired.
[0065] The present invention provides a miniature C2C9 nuclease for use in a CRISPR editing system, which comprises i) an RNA-binding portion that interacts with a gRNA, and an active portion.
[0066] The C2C9 nuclease has at least one activity such as an activity of regulating transcription in a target gene (e.g., a target DNA), a cleavage activity (an endoribonuclease and / or an endonuclease activity), a gene editing activity, etc., and the types of gene editing that can be realized include, but are not limited to, gene cleavage, gene deletion, gene insertion, point mutation, transcription repression, transcription activation, and base editing. The C2C9 nuclease may be derived from any biological species.
[0067] As a non-limiting example, the C2C9 nuclease is useful, for example, as a nuclease in a CRISPR editing system.
[0068] In the present invention, variants of C2C9 nuclease can be formed by means of modification, mutation, DNA recombination, etc., so that the variants of C2C9 nuclease have improved desired characteristics, such as function, activity, kinetics, half-life, etc. The modification can be, for example, amino acid deletion, insertion, or substitution, and can also be, for example, replacing the "cleavage domain" of C2C9 nuclease with a homologous or heterologous cleavage domain from a different nuclease (e.g., the HNH domain of a CRISPR-associated nuclease). Any modification method of DNA-binding and / or DNA-modifying proteins known in the art, such as methylation, demethylation, acetylation, etc., can, for example, change the DNA targeting of C2C9 nuclease. The DNA recombination refers to the exchange of sequence fragments between DNA sequences of C2C9 nucleases from different origins to generate a chimeric DNA sequence encoding a synthetic protein with RNA-guided endonuclease activity. The above modifications, mutations, DNA recombinations, etc. may be used alone or in combination.
[0069] The C2C9 nuclease comprises, from the N-terminus to the C-terminus: The amino acid sequence shown in SEQ ID NO: 1 or the amino acid sequence having at least 30% Domain 1, including variants having at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% sequence identity with any of the domains; Domain 2, comprising the amino acid sequence set forth in SEQ ID NO:2 or a variant having at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% sequence identity to said amino acid sequence.
[0070] The variant of C2C9 nuclease may be: (I) A variant that has at least 20% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity with the amino acid sequence of wild-type C2C9 nuclease and retains the activity of wild-type C2C9 nuclease; (II) In the C2C9 nuclease or variant thereof described in (I) above, a variant containing other components, for example, a nuclear localization signal fragment, so that the constructed C2C9CRISPR system has appropriate activity in a cell-free reaction, a prokaryotic cell, or a eukaryotic cell environment; (III) codon-optimized variants of the corresponding polynucleotide sequences of the wild-type C2C9 nuclease or variants of (I) and (II) above; (IV) The above wild-type C2C9 nuclease and any one of variants (I) to (III), further comprising: (a) one or more modifications or mutations that produce a C2C9 with significantly reduced or undetectable nuclease activity, and (b) A polypeptide or domain having another functional activity. The suitable polypeptide in (IV)(b) is linked to the C-terminal domain of C2C9 nuclease and its variants.
[0071] The variant of C2C9 nuclease in (IV) can convert any base into any other possible base pair by modification or mutation, rather than by introducing a double-strand break into the target DNA sequence.
[0072] The variant of C2C9 nuclease in (IV) may be a fusion or chimeric polypeptide consisting of a wild-type C2C9 nuclease or a variant of (I) to (III) and a heterologous sequence. The heterologous sequence includes, but is not limited to, a light-induced transcription regulator, a small molecule / drug-responsive transcription regulator, a transcription factor, a transcription inhibitor protein, etc. When forming a fusion or chimeric polypeptide, the wild-type C2C9 nuclease or a variant of (I) to (III) may be a complete C2C9 nuclease or a part thereof or a completely defective one. For example, a C2C9 nuclease containing a catalytically active endonuclease domain may be fused to a Fokl domain to form a chimeric protein, or a C2C9 nuclease modified to lose endonuclease domain activity may be fused to a Fokl domain to form a chimeric protein, or epigenetic modifiers, tags, imaging agents, transcriptional regulators, histones, or other components that modulate gene domain activity may be fused to C2C9 nuclease to produce a chimeric protein. In some embodiments, the heterologous sequence may provide a tag (e.g., a fluorescent protein such as green fluorescent protein (GFP), YFP, RFP, CFP, His tag, hemagglutinin (HA) tag, FLAG tag, Myc tag, etc.) that is easy to track or purify. In some embodiments, the heterologous sequence may provide subcellular localization of the C2C9 nuclease.
[0073] In some embodiments, the variant of C2C9 nuclease is a modified version of C2C9 nuclease. In some embodiments, the modified version of C2C9 nuclease comprises amino acid changes that reduce the naturally occurring nuclease activity of C2C9 nuclease. For example, in some embodiments, the modified version of C2C9 nuclease has less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5% or less than 1% of the nuclease activity of the corresponding wild-type C2C9 nuclease. In some embodiments, the modified version of C2C9 nuclease does not have significant nuclease activity, but still has the ability to interact with gRNA. In some embodiments, the modified version of C2C9 nuclease does not have nuclease activity. In one embodiment, a mutant polypeptide has altered or eliminated DNA endonuclease activity where the endoribonuclease activity or binding affinity for DNA of the C2C9 nuclease is not significantly reduced or enhanced.
[0074] In some embodiments, the C2C9 may be used in combination with other enzyme components or other components to further develop various potential applications of the C2C9 nuclease. Non-limiting examples of the variant of C2C9 nuclease in (IV) include, for example, development of a single base editing system based on C2C9 nuclease by fusing inactivated C2C9 with base deaminase, a Prime editing system based on C2C9 nuclease by fusing inactivated C2C9 with reverse transcriptase, a transcription activation system based on C2C9 nuclease by fusing inactivated C2C9 with a transcription activator, an epigenetic system based on C2C9 nuclease by fusing inactivated C2C9 with a nucleic acid epigenetic enzyme, and a transcription repression system based on C2C9 nuclease using inactivated C2C9.
[0075] Variants of C2C9 nuclease may have certain properties, including but not limited to the following: have an enhanced or decreased ability to bind to a target site, or have residual ability to bind to a target site; have enhanced or decreased endoribonuclease and / or endonuclease activity or have residual endoribonuclease and / or endonuclease activity; It has deaminase activity that can act on cytosine, guanine, or adenine bases, and replicates and repairs them intracellularly via the deamination site to produce guanine, thymine, and guanine, respectively; has an activity of regulating the transcription of a target DNA, and may increase or decrease the transcription of the target DNA at a specific position in the target DNA; have altered DNA targeting; Increased or decreased or maintained stability; capable of cleaving the complementary strand of the target DNA, but has a reduced ability to cleave the non-complementary strand of the target DNA; capable of cleaving the non-complementary strand of the target DNA, but has a reduced ability to cleave the complementary strand of the target DNA; Has the ability to cleave both complementary and non-complementary strands of reduced target DNA; The nuclease may have an enzymatic activity that modifies a polypeptide associated with DNA (e.g., a histone), and the enzymatic activity may be one or more of methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitination activity, ribosylation activity, etc. (these enzymatic activities catalyze covalent modifications to proteins; for example, variants of C2C9 nuclease may modify histones by methylation, acetylation, ubiquitination, phosphorylation, etc., thereby causing changes in the structure of histone-associated DNA, thereby regulating the structure and properties of DNA).
[0076] In some embodiments, the variant of C2C9 nuclease has no cleavage activity. In some embodiments, the variant of C2C9 nuclease has single-strand cleavage activity. In some embodiments, the variant of C2C9 nuclease has double-strand cleavage activity.
[0077] Having enhanced activity or potency means having at least 1%, 5%, 10%, 20%, 30%, 40%, 50% improved activity or potency relative to wild-type C2C9 nuclease.
[0078] Having reduced activity and potency means having less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5% or less than 1% of the activity or potency of wild-type C2C9 nuclease.
[0079] In the present invention, the C2C9 nuclease is preferably derived from the group consisting of SEQ ID NOs: 3 to 117 and the like.
[0080] In certain embodiments, C2C9 nucleases from different species are advantageous in providing different applications, e.g., increased or decreased enzyme catalytic activity, increased or decreased levels of cytotoxicity, altered balance between NHEJ, homology directed repair, single-strand breaks, double-strand breaks, etc., because they take advantage of the various enzymatic properties of different C2C9 nucleases (e.g., preference for different PAM sequences).
[0081] In some embodiments, the C2C9 nuclease is from Actinomadura craniellae and includes the amino acid sequence of SEQ ID NO:3 or a variant having at least about 90% (e.g., at least about any of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity to SEQ ID NO:3, and Actinomadura craniellae C2C9 or "AcC2C9" can recognize the PAM sequence AAN. In some embodiments, the C2C9 nuclease is from Corynebacterium glutamicum (SEQ ID NO:5), and Corynebacterium glutamicum C2C9 or "CgC2C9" can recognize the PAM sequence AAN. In some embodiments, the C2C9 nuclease is from Rothia dentocariosa (SEQ ID NO:20), and Rothia dentocariosa C2C9 or "RdC2C9" can recognize the PAM sequence AAG. In some embodiments, the RdC2C9 nuclease can recognize the PAM sequence AAA, AAT, or AAC. In some embodiments, the C2C9 is from Micrococcus luteus (SEQ ID NO: 12), and Micrococcus luteus C2C9 or "MiC2C9" can recognize the PAM sequence AAN. The AAN includes AAA, AAC, AAG, and AAT.
[0082] For a particular C2C9 nuclease selected, the PAM sequence requirements may differ from the PAM sequence described above, since C2C9 nucleases from different species or different C2C9 nucleases from the same species may require different PAM sequences in the target DNA.
[0083] In certain embodiments, these small C2C9s may be used in any of the systems, compositions, kits and methods of the invention described below.
[0084] In one preferred embodiment, the C2C9 nuclease is Actinomadura craniellae, its sequence is AcC2C9, and its sequence is shown in SEQ ID NO:3 in the sequence listing.
[0085] In one embodiment, the variant of AcC2C9 nuclease is: (I) A variant having at least 20% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%) sequence identity with the amino acid sequence of the wild-type AcC2C9 nuclease of SEQ ID NO:3 and having increased, decreased or maintained activity relative to the wild-type AcC2C9 nuclease; (II) The AcC2C9 nuclease or a variant thereof described in (I) above, further comprising other components, such as a variant containing a nuclear localization signal, so that the constructed C2C9CRISPR system has appropriate activity in a cell-free reaction, a prokaryotic cell, or a eukaryotic cell environment; (III) a codon-optimized variant of the corresponding polynucleotide sequence of the wild-type AcC2C9 nuclease of SEQ ID NO: 3 or the variants of (I) and (II) above; (IV) A variant of the wild-type AcC2C9 nuclease of SEQ ID NO: 3 and any one of (I) to (III), further comprising: (a) one or more modifications or mutations that produce a C2C9 with significantly reduced or undetectable nuclease activity, and (b) A polypeptide having another functional activity.
[0086] The C2C9 nuclease provided by the present invention has a small number of amino acids. In one preferred embodiment, when the amino acid sequence of the C2C9 nuclease is shown in SEQ ID NO: 3, it interacts with the PAM sequence AAN. The cleavage site is usually located within 1-3 base pairs upstream of the PAM sequence. For a particular C2C9 nuclease selected, the PAM sequence requirements may differ from the PAM sequence, since C2C9 nucleases from different species or different C2C9 nucleases from the same species may require different PAM sequences in the target DNA. C2C9 can be engineered to target the PAM sequence "AAN" or other suitable target PAM sequences.
[0087] In one embodiment, the AcC2C9 nuclease variant has at least 90% (e.g., at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity to the amino acid sequence set forth in SEQ ID NO: 3 and retains AcC2C9 nuclease activity.
[0088] Unless otherwise stated, the terms "C2C9" and "C2C9 nuclease" include wild-type C2C9 nuclease and all its variants, and a person skilled in the art can determine the type of C2C9 nuclease variant by routine means, including but not limited to those listed above.
[0089] The present invention also provides nucleic acids comprising nucleotides encoding AcC2C9 nuclease. In one embodiment, the present invention provides codon-optimized polynucleotide sequences that encode one or more functional C2C9 domains or that encode polypeptides having similar functions as those encoded by the original native nucleotide sequence. Thus, one skilled in the art can use the C2C9 nuclease described in the present invention in a specific target species to perform codon optimization on nucleotide sequences or recombinant nucleic acids. Other methods known in the art may be used to optimize codons to have less than 100% (e.g., less than 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) identity to the native nucleotide sequence SEQ ID NO: 121. The polynucleotides of the present invention are codon-optimized to increase expression of the encoded C2C9 nuclease in the target cell. In one embodiment Thus, the polynucleotides of the invention are codon optimized for increased expression in human cells. In one embodiment, the polynucleotides of the invention are codon optimized for increased expression in E. coli cells. In one embodiment, the polynucleotides of the invention are codon optimized for increased expression in fungal cells. In one embodiment, the polynucleotides of the invention are codon optimized for increased expression in insect cells.
[0090] In one embodiment, the nucleic acid encoding the AcC2C9 nuclease is shown in SEQ ID NO: 122 in the sequence listing. In one embodiment, the present invention provides a codon-optimized polynucleotide sequence of AcC2C9 nuclease, which has at least 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.2%, 99.5%, 99.8%, 99.9% or 100% sequence identity with SEQ ID NO: 121. In one preferred embodiment, a more preferred human codon-optimized coding sequence of the AcC2C9 nuclease is shown in SEQ ID NO: 122 in the sequence listing, which encodes one or more functional C2C9 domains or encodes a polypeptide having similar function to the polypeptide encoded by the original native nucleotide sequence. In one embodiment, the polynucleotide encoding the C2C9 nuclease has sequence identity of at least about 90% (e.g., at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) to SEQ ID NOs: 121-122.
[0091] In some embodiments, the nucleic acid encoding the C2C9 nuclease is DNA. In some embodiments, the nucleic acid encoding the C2C9 nuclease is RNA. In some embodiments, the nucleic acid encoding the C2C9 nuclease is an expression vector, e.g., a recombinant expression vector. Any suitable expression vector compatible with the host cell may be used, including, but not limited to, viral vectors (e.g., viral vectors based on vaccinia virus, poliovirus, adenovirus, adeno-associated virus, SV40, herpes simplex virus, human immunodeficiency virus, retroviral vectors (e.g., murine leukemia virus, spleen necrosis virus, and vectors derived from retroviruses, e.g., Rous sarcoma virus, Harvey sarcoma virus, avian leukosis virus, lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus), and the like.
[0092] In some embodiments, the nucleotide sequence encoding the C2C9 nuclease is operably linked to a control element, e.g., a transcription control element, e.g., a promoter. In some embodiments, the nucleotide sequence encoding the C2C9 nuclease is operably linked to an inducible promoter. In some embodiments, the nucleotide sequence encoding the C2C9 nuclease is operably linked to a constitutive promoter. The transcription control element may function in eukaryotic cells, e.g., mammalian cells, or prokaryotic cells, e.g., bacterial or archaeal cells. In some embodiments, the nucleotide sequence encoding the C2C9 nuclease is operably linked to multiple control elements such that the nucleotide sequence encoding the C2C9 nuclease is expressed in both prokaryotic and eukaryotic cells. In some embodiments, the polynucleotide sequence encoding the C2C9 nuclease is operably linked to an appropriate nuclear localization signal for expression in a cell or in an extracellular environment.
[0093] In the present invention, the polynucleotide sequence encoding the C2C9 nuclease can be synthesized by artificial synthesis means, for example, by chemical methods, so that many modifications can be easily made to the polynucleotide sequence. The modification may be any modification mode known in the art. In one embodiment, the C2C9 nuclease can be synthesized by The encoding polynucleotide sequence includes one or more modifications to facilitate the introduction of many modifications, such as enhanced transcriptional activity, altered enzymatic activity, improved translation or stability (e.g., resistance to proteolysis, degradation) or specificity, altered solubility, altered delivery, or reduced innate immune response in host cells. The modification may be any modification known in the art. In some embodiments, the DNA or RNA encoding C2C9 nuclease that is introduced into cells by modification edits any one or more genomic loci. In some embodiments, the nucleic acid sequence encoding C2C9 nuclease is a modified nucleic acid, such as a codon-optimized one. The modification may be a single modification or a combination of modifications.
[0094] In the present invention, a nucleic acid comprising a polynucleotide encoding a C2C9 nuclease may be a nucleic acid mimetic, such as a peptide nucleic acid, which is a polynucleotide mimetic having excellent hybridization properties.
[0095] In the present invention, the C2C9 nuclease or the polynucleotide encoding the C2C9 nuclease is applied to any organism or in vitro environment, including but not limited to bacteria, archaea, fungi, protists, plants or animals. Correspondingly, the target cells applied include but are not limited to eukaryotic cells and prokaryotic cells, such as bacterial cells, archaea cells, fungal cells, protist cells, plant cells or animal cells. The fungal cells include mammalian cells and plant cells, and the prokaryotic cells include Escherichia coli and Klebsiella pneumoniae. The target cells applied may be any type of cell, including stem cells, somatic cells, etc. The cells may be in vivo or in vitro. In one embodiment, the C2C9 nuclease or the nucleic acid encoding the C2C9 nuclease is prepared in a liposome or lipid nanoparticle.
[0096] The present invention also provides the use of the C2C9 nuclease in constructing a CRISPR / C2C9 gene editing system.
[0097] The present invention also provides PAM sequences suitable for use in an in vivo, in vitro cellular or in vitro environment, which PAM sequences are AAN and / or GAN.
[0098] The present invention also provides suitable PAM sequences and suitable guides in prokaryotic, eukaryotic and in vitro environments. The guide RNA (gRNA) provided by the present invention guides a nuclease, e.g., C2C9 nuclease, to a specific target sequence in a target gene.
[0099] In one embodiment, the gRNA comprises: a first fragment of a nucleotide sequence that is complementary to a target sequence in the target gene (also referred to as a "gene target sequence" or "gene target fragment"); and A second fragment (also called the "protein binding sequence" or "protein binding fragment") that interacts with C2C9 nuclease.
[0100] In one embodiment, the gRNA comprises a repeat spacer array, where the spacer comprises a nucleic acid sequence complementary to a target sequence in a gene.
[0101] In one embodiment, the gRNA comprises: i. a gene target region (e.g., a DNA-target region) capable of hybridizing to the target sequence; ii. a tracr mate sequence; and iii. tracrRNA sequence, The guide RNA is single-stranded and is composed of the DNA-target region (i), the tracr mate sequence (ii) and the tracrRNA sequence (iii) linked in this order; or The tracrRNA contains two strands, one of which is composed of the gene target region (i) and the tracr mate sequence (ii) linked thereto, and the other strand is the tracrRNA sequence (iii).
[0102] Here, said gene target region (i) is preferably an RNA sequence corresponding to a nucleic acid fragment having a length of 20 bp following a PAM sequence.
[0103] Here, the tracr mate sequence (ii) hybridizes with the tracrRNA sequence (iii) to form a stem-loop structure.
[0104] Here, the tracr mate sequence (ii) can be integrally linked to the tracrRNA sequence (iii) to form a single guide RNA backbone sequence.
[0105] Here, the RNA sequence (crRNA) in which the gene target region (i) that hybridizes with the target sequence and the tracr mate sequence (ii) are linked, and the tracrRNA sequence (iii) can mediate C2C9 endonuclease activity when they are present simultaneously as two independent RNA sequences. Alternatively, the complete guide RNA expression construct for the target sequence obtained by linking the guide RNA backbone sequence and the DNA-target region (i) that hybridizes with the target sequence can also mediate C2C9 endonuclease activity.
[0106] The gene targeting region of gRNA comprises a nucleotide sequence complementary to a sequence in a target gene, and the gene targeting region interacts with the target gene in a sequence-specific manner by hybridizing (i.e., base pairing). For example, the gene targeting region of gRNA can be modified by genetic engineering means so that the gRNA hybridizes with any required sequence in the target gene. The gRNA guides the bound polypeptide via the gene targeting sequence to a specific nucleotide sequence in the target gene.
[0107] The stem-loop structure forms a protein-binding structure that interacts with C2C9 nuclease. In one embodiment, the protein-binding structure of the gRNA comprises four stem-loop structures, and the tracr mate sequence (ii) is usually paired with the tracrRNA sequence (iii) by complementary base pairing. The activity of C2C9 nuclease can be improved or non-specific recognition can be reduced by modifying the base sequence of the gRNA.
[0108] In some embodiments, the target gene is a DNA sequence. In some embodiments, the target gene is an RNA sequence.
[0109] In one embodiment, the gRNA is an sgRNA. In one preferred embodiment, the sequence of the gRNA is set forth in SEQ ID NO: 123.
[0110] In some embodiments, the target sequence of the target gene may have a length of 12 to 40 nucleotides, for example, 13 to 20, 18 to 25, 22 to 32, 26 to 37, 30 to 38, 32 to 40 nucleotides in length. The percentage of complementarity between the target region (i) of the guide RNA and the target sequence of the target gene may be at least 50% (e.g., at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99% or 100%).
[0111] In one embodiment, the gRNA further comprises a transcription terminator.
[0112] The present invention also provides modified gRNAs that can be modified to hybridize with any required sequence in a target gene; or that can modify the properties of the gRNA itself, including, but not limited to, increasing the stability of the gRNA by modifying it to increase resistance to degradation by ribonucleases (RNases) present in cells, thereby extending its half-life in cells; or that can be modified to increase the formation or stability of a CRISPR-C2C9 genome editing complex comprising a gRNA and an endonuclease (e.g., C2C9 nuclease); or that can increase the specificity of the genome editing complex; or that can increase the initiation site, stability or kinetics of the interaction between the genome editing complex and a target sequence in a genome; or that can reduce the likelihood or extent of an innate immune response caused by RNA introduced into a cell. In the present invention, gRNA can be modified to modify many properties of the CRISPR-C2C9 system (as described below), for example, to enhance the formation, target activity, specificity, stability or kinetic properties of the CRISPR-C2C9 genome editing complex. RNA can be modified by modification means known in the art, including but not limited to 2'-fluoro, 2'-amino modifications at the ribose of pyrimidines, base residues or the reverse base at the 3' end of the RNA. In the present invention, gRNA can be modified by any one modification or a combination of multiple modifications. In some embodiments, the sgRNA introduced into the cell by modification edits any one or more genomic loci.
[0113] The present invention provides a nucleic acid comprising a nucleotide sequence encoding a gRNA. In certain embodiments, the nucleic acid encoding the gRNA is an expression vector, e.g., a recombinant expression vector. Any suitable expression vector may be used, provided it is compatible with the host cell, including, but not limited to, viral vectors (e.g., viral vectors based on vaccinia virus, poliovirus, adenovirus, adeno-associated virus, SV40, herpes simplex virus, human immunodeficiency virus, retroviral vectors (e.g., murine leukemia virus, spleen necrosis virus, and vectors derived from retroviruses, e.g., Rous sarcoma virus, Harvey sarcoma virus, avian leukosis virus, lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus), and the like.
[0114] In some embodiments, multiple gRNAs are used simultaneously in the same cell to regulate the transcription of different positions in the same target gene or different target genes at the same time.When multiple gRNAs are used simultaneously, they can be present in the same expression vector or different expression vectors and can be expressed at the same time.When they are present in the same vector, they can be expressed in the same control element.
[0115] In some embodiments, the nucleotide sequence encoding the gRNA is operably linked to a control element, e.g., a transcription control element, e.g., a promoter. In some embodiments, the nucleotide sequence encoding the gRNA is operably linked to an inducible promoter. In some embodiments, the nucleotide sequence encoding the gRNA is operably linked to a constitutive promoter. The transcription control element can be functional in a eukaryotic cell, e.g., a mammalian cell, or a prokaryotic cell (e.g., a bacterial or archaeal cell). In some embodiments, the nucleotide sequence encoding the gRNA is operably linked to multiple control elements such that the nucleotide sequence encoding the gRNA is expressed in both prokaryotic and eukaryotic cells.
[0116] In the present invention, the gRNA is synthesized by artificial synthesis means, for example, by chemical methods, so that many modifications can be easily made to the gRNA. The modification can be any modification means known in the art, such as the use of a polyA tail, the addition of a 5' cap analog, a 5' or 3' untranslated region (UTR), a thiophosphorylated 2'-O-methyl nucleotide contained in the 5' or 3' end, or removal of the 5' end phosphate by phosphatase treatment.
[0117] In certain embodiments, the nucleotide sequence encoding the gRNA contains one or more modifications that are used, for example, to enhance activity, stability or specificity, alter delivery, reduce or otherwise enhance an innate immune response in a host cell.
[0118] In some embodiments, one or more targeting moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the nucleotide sequence encoding the gRNA are chemically linked to the gRNA. The targeting moiety or conjugate may include a conjugate group that is covalently linked to the functional group, including a reporter molecule, a polyamine, and a polyethylene glycol. In some embodiments, a group that enhances a pharmacological property is linked to the gRNA, including a group that improves uptake, a group that enhances resistance to degradation, and / or a group that enhances sequence-specific hybridization with the target nucleic acid.
[0119] In the present invention, the nucleic acid comprising a polynucleotide encoding a gRNA may be a nucleic acid mimetic, such as a peptide nucleic acid, which is a polynucleotide mimetic having excellent hybridization properties.
[0120] In the present invention, the gRNA or the polynucleotide encoding the gRNA is applied to any organism or in vitro environment, including but not limited to bacteria, archaea, fungi, protists, plants or animals. Correspondingly, the target cells applied include but are not limited to bacterial cells, archaea cells, fungal cells, protists, plants or animals. The target cells applied can be any type of cell, including stem cells, somatic cells, etc.
[0121] The present invention also provides a recombinant expression vector, comprising (i) a nucleotide sequence encoding a gRNA, and (ii) a nucleotide sequence encoding a C2C9 nuclease. In one embodiment, the site of transcription regulation in a target gene is determined by the gRNA.
[0122] The present invention also provides a CRISPR-C2C9 system based on C2C9 nuclease, comprising (a) a nucleic acid comprising the C2C9 nuclease or a polynucleotide encoding the C2C9 nuclease, and / or (b) one or more gRNAs or nucleic acids encoding the gRNAs, wherein the gRNAs are capable of guiding the C2C9 nuclease to a target sequence.
[0123] In some embodiments, the C2C9 nuclease is provided as a protein itself. For example, exogenous proteins for spheroplast transformation and / or nucleic acid transformation fungi may be used. The C2C9 nuclease can be introduced into cells by any suitable method, such as by injection.
[0124] In the system described in the present invention, C2C9 nuclease and gRNA can form a complex in a host cell and recognize a PAM sequence in the sequence of a target gene (e.g., a target DNA). The target sequence of the CRISPR / C2C9 gene editing system is a nucleic acid fragment (e.g., a DNA fragment) with a length of 20 bp following a PAM sequence. In one embodiment, the complex can selectively regulate the transcription of the target DNA in a host cell. The CRISPR / C2C9 gene editing system cuts the double strand of the target DNA, leading to DNA breaks. The target strand (a DNA single strand that complementarily pairs with the gRNA, Tar The primary cleavage site of the non-targeting strand (also called the gRNA strand or TS strand) is 21-22 nt downstream of the 3' end of the PAM site, whereas the primary cleavage site of the non-targeting strand (a single strand of DNA that does not complementarily pair with the gRNA, also called the non-targeting strand or NTS strand) is 15-16 nt downstream of the 3' end of the PAM site.
[0125] In one embodiment, the system comprises a complex of a gRNA and a C2C9 nuclease.
[0126] In one embodiment, the system includes a recombinant expression vector. In one embodiment, the system includes a recombinant expression vector, the recombinant expression vector includes (i) a nucleotide sequence encoding a gRNA, and (ii) a nucleotide sequence encoding a C2C9 nuclease, the gRNA includes (a) a first region including a nucleotide sequence complementary to a sequence in a target DNA, and (b) a second region that interacts with the C2C9 nuclease, the C2C9 nuclease includes (a) an RNA-binding portion that interacts with the gRNA, and (b) an activity portion that regulates transcription in the target DNA, where the site of regulation of transcription in the target DNA is determined by the gRNA.
[0127] In some embodiments, the system comprises (or consists of) a C2C9 nuclease as set forth in SEQ ID NO:3. In some embodiments, the system comprises a nucleic acid encoding a C2C9 nuclease, the nucleic acid having at least about 90% (e.g., at least about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence homology to SEQ ID NO:121 or SEQ ID NO:122. In some embodiments, the system comprises a nucleic acid encoding a C2C9 nuclease, the nucleic acid comprising (or consisting of) the sequence of SEQ ID NO:121 or SEQ ID NO:122. In some embodiments, the gRNA in the system is a single gRNA (sgRNA). In some embodiments, the system further comprises one or more additional gRNAs or a nucleic acid encoding one or more additional gRNAs.
[0128] In one embodiment, the system comprises a suitable promoter and / or a suitable nuclear localization signal for expression in a cell or in an extracellular environment, and the polynucleotide sequence encoding the C2C9 nuclease is operably linked to (i) a suitable promoter for expression in a cell or in an extracellular environment, and / or (ii) a suitable nuclear localization signal.
[0129] In one embodiment, in the system, the polynucleotide sequence encoding the gRNA is operably linked to (i) a suitable promoter for expression in a cell or in an extracellular environment, and / or (ii) a suitable nuclear localization signal.
[0130] In one embodiment, the present invention provides a system comprising: (a) a C2C9 nuclease comprising the amino acid sequence of SEQ ID NO: 3 or a variant having at least 90% sequence homology to SEQ ID NO: 3; and (b) a gRNA capable of guiding the C2C9 nuclease or variant thereof to a target polynucleotide sequence.
[0131] In one embodiment, the present invention provides a nucleic acid encoding a C2C9 nuclease comprising the amino acid sequence of SEQ ID NO: 3 or a variant having at least 90% sequence identity with SEQ ID NO: 3, or a polynucleotide sequence of any one of SEQ ID NO: 121 or SEQ ID NO: 122 or a variant having at least 90% sequence identity with the polynucleotide sequence of any one of SEQ ID NO: 121 or SEQ ID NO: 122, and (b) a gRNA or a nucleic acid encoding a gRNA capable of guiding said C2C9 nuclease or variant thereof to a target polynucleotide sequence. In one embodiment, the gRNA is an sgRNA.
[0132] The system according to the present invention may comprise one gRNA or may comprise multiple gRNAs at the same time. In one embodiment, the system comprises multiple gRNAs at the same time to simultaneously modify different positions on the same target DNA or different target DNAs. In one embodiment, two or more guide RNAs target the same gene or transcript or locus. In one embodiment, two or more guide RNAs target different unrelated loci. In one embodiment, two or more guide RNAs target different but related loci.
[0133] Each component part in the system described in the present invention can be delivered by means of a vector. For example, for polynucleotides, methods that can be used include, but are not limited to, nanoparticles, liposomes, ribonucleoproteins, small molecule RNA-conjugates, chimeras, and RNA-fusion protein complexes.
[0134] In some embodiments, the C2C9 or gRNA is constructed in a vector, and the nucleotide sequence encoding the C2C9 and / or gRNA may be operably linked to a control element, e.g., a transcription control element, e.g., a promoter. The transcription control element may be functional in eukaryotic cells (e.g., mammalian cells) or prokaryotic cells (e.g., bacterial or archaeal cells). In some embodiments, the nucleotide sequence encoding the gRNA and / or the C2C9 nuclease is operably linked to multiple control elements such that the nucleotide sequence encoding the guide RNA and / or the localization modifying polypeptide is expressed in two prokaryotes. In some embodiments, the nucleotide sequence encoding the gRNA and / or the C2C9 nuclease is constructed in the same vector. In some embodiments, the nucleotide sequence encoding the gRNA and / or the C2C9 nuclease is constructed in different vectors. In some embodiments, the nucleotide sequence encoding the gRNA and / or the C2C9 nuclease is operably linked to a constitutive promoter. In one embodiment, the nucleotide sequence encoding the gRNA and / or the C2C9 nuclease is operably linked to an inducible promoter.
[0135] The system according to the invention may further comprise one or more donor templates. In some embodiments, the donor template comprises a donor sequence for insertion into a target gene. In some embodiments, the donor template comprises a donor cassette, the donor cassette being flanked on one or both sides by a gRNA target site. In some embodiments, the donor template is flanked on both sides by a gRNA target site, where the gRNA target site of the donor template is the reverse complement of the genomic gRNA target site of the gRNA in the system. The donor sequence is usually different from the genomic sequence it replaces, i.e., the donor sequence usually contains base modifications, insertions, deletions, inversions or transpositions to the genomic sequence, and has sufficient homology for homology directed repair. The donor sequence may be single-stranded DNA, single-stranded RNA, double-stranded DNA or double-stranded RNA. In some embodiments, the donor sequence is an exogenous sequence. In some embodiments, the donor sequence is a donor DNA sequence (including donor single-stranded or double-stranded DNA), where the target DNA sequence is edited by homology-directed repair. In some embodiments, the donor template is physically linked to the gRNA in the system. In some embodiments, the complete C2C9 nuclease or a part or a complete defective one, or the gRNA is linked to the donor template to facilitate homologous recombination of the exogenous DNA sequence by guiding it to the site of one or more specific target genes (e.g., target DNA) by one or more gRNA molecules.
[0136] The system according to the present invention further comprises a dimeric FOK1 nuclease, and 9 nuclease or a partially or completely defective C2C9 nuclease, or gRNA linked to a dimeric FOK1 nuclease may be guided to one or more specific DNA target sites by one or more gRNA molecules to guide endonucleolytic cleavage.
[0137] The systems described herein can be used in gene therapy by editing or modifying DNA at multiple locations in a cell, including, but not limited to, gene therapy for disease, biological research, improving resistance and yield in agricultural crops, etc.
[0138] In the present invention, the system is applied to any organism or in vitro environment, including but not limited to bacteria, archaea, fungi, protists, plants or animals. Correspondingly, the target cells applied include but are not limited to bacterial cells, archaea cells, fungal cells, protists, plants or animals. The target cells applied can be any type of cells, including stem cells, somatic cells, etc. The cells can be in the body or in vitro.
[0139] The present invention also provides a composition comprising one or more of the above-mentioned C2C9 nuclease or a polynucleotide encoding it, gRNA or a polynucleotide encoding it, a recombinant expression vector, and a system, and may further comprise an acceptable carrier, medium, etc. The acceptable carrier, medium may include, for example, sterile water or physiological saline, a stabilizer, an excipient, an antioxidant (such as ascorbic acid), a buffer (such as phosphoric acid, citric acid, other organic acids, etc.), a preservative, a surfactant (such as PEG, Tween, etc.), a chelating agent (such as EDTA), a binder, etc. The acceptable carrier, medium may also include other low molecular weight polypeptides, proteins such as serum albumin, gelatin, or immunoglobulin, amino acids such as glycine, glutamine, asparagine, arginine, and lysine, sugars or carbohydrates such as polysaccharides and monosaccharides, and sugar alcohols such as mannitol and sorbitol. When preparing an aqueous solution for injection, for example, an isotonic solution containing physiological saline, glucose, or other auxiliary drugs such as D-sorbitol, D-mannose, D-mannitol, or sodium chloride may be used, or a suitable solubilizing agent such as alcohol (e.g., ethanol), polyhydric alcohol (e.g., propylene glycol, PEG, etc.), nonionic surfactant (Tween 80, HCO-50), etc. may be used in combination. In one embodiment, the composition includes a buffer that stabilizes the gRNA and the nucleic acid.
[0140] The present invention also provides a kit comprising the above-mentioned system or composition. The kit may further comprise one or more of other reagents, such as a dilution buffer, a washing buffer, and a control reagent. In one embodiment, the kit comprises (a) a C2C9 nuclease or a nucleic acid encoding the C2C9 nuclease as described above, and (b) a gRNA or a nucleic acid encoding the gRNA, wherein the gRNA can guide the C2C9 nuclease or a variant thereof to a target polynucleotide sequence. In one embodiment, the kit further comprises a donor template comprising a foreign polynucleotide sequence, wherein the foreign polynucleotide sequence is capable of being inserted into the target polynucleotide sequence.
[0141] The present invention provides the use of the aforementioned C2C9 nuclease or a polynucleotide encoding same, gRNA or a polynucleotide encoding same, recombinant expression vectors, systems, compositions and kits for use in any one of the following applications in the body, in an in vitro cell or in a cell-free system, including, but not limited to: cleaving a target gene; Regulating the expression of target genes; Genetically modifying target genes; Genetically modifying a target gene-related polypeptide; Intentional and controlled damage at any desired location in the target gene; Deliberate and controlled repair at any desired location in the target gene; The target gene is modified by means other than introducing a double-strand break (C2C9 nuclease has enzymatic activity and modifies the target gene by means other than introducing a double-strand break. The enzymatic activity may be that possessed by C2C9 itself or may be obtained, for example, by fusing a heterologous polypeptide having enzymatic activity to C2C9 nuclease to form a chimeric C2C9 nuclease, and the enzymatic activity may include, but is not limited to, methyltransferase activity, deamination activity, dismutase activity, alkylation activity, demethylase activity, DNA repair activity, transposase activity, recombinase activity, DNA damage activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, etc.).
[0142] In some embodiments, the target gene is a target DNA. In some embodiments, the target gene is a target RNA.
[0143] In the present invention, the C2C9 may be used in combination with other enzyme components or other components to further develop various potential applications of C2C9 nuclease. Non-limiting examples include the development of a single base editing system based on C2C9 nuclease by fusing inactivated C2C9 with base deaminase, a Prime editing system based on C2C9 nuclease by fusing inactivated C2C9 with reverse transcriptase, a transcription activation system based on C2C9 nuclease by fusing inactivated C2C9 with a transcription activator, an epigenetic system based on C2C9 nuclease by fusing inactivated C2C9 with a nucleic acid epigenetic enzyme, and a transcription repression system based on C2C9 nuclease using inactivated C2C9.
[0144] The C2C9 nuclease or polynucleotide encoding it, gRNA or polynucleotide encoding it, recombinant expression vector, system, composition and kit of the present invention can be used in research, diagnostics, industry (e.g., microbiome engineering), drug discovery (e.g., high-throughput screening), target validation, imaging and therapeutics, etc. Research uses may be, for example, to determine the effect of upregulation of transcription of a target nucleic acid on, for example, development, growth, metabolism (e.g., precisely controlling and regulating biosynthetic pathways by controlling the levels of certain enzymes), gene expression, etc.
[0145] In the present invention, the C2C9 nuclease or the polynucleotide encoding it, gRNA or the polynucleotide encoding it, recombinant expression vector, system, composition and kit, etc. can be applied to any organism, including but not limited to bacteria, archaea, fungi, protists, plants or animals. Correspondingly, the target cells applied include but are not limited to bacterial cells, archaea cells, fungal cells, protists, plants or animals (e.g., rodent cells, human cells, non-human primate cells). The target cells applied can be any type of cell, including stem cells, somatic cells, etc.
[0146] When the C2C9 nuclease, gRNA, system, composition and method described in the present invention are applied to eukaryotic cells, they may be used, for example, in mammalian cells. In some embodiments, the cells are not human fetal cells or are not derived from human fetal cells. In some embodiments, the cells are not human embryonic cells or are not derived from human embryonic cells. In some embodiments, the present invention does not relate to the destruction of a human fetus or human embryo. In some embodiments, the subject or individual is not a human fetus or embryo.
[0147] The C2C9 nuclease according to the present invention or a polynucleotide encoding the same, gRN A or its encoding polynucleotides, recombinant expression vectors, systems, compositions and kits, etc., are applied to prokaryotic cells, for example, E. coli. In some embodiments, it is used to block gene expression in bacterial cells. In some embodiments, a nucleic acid encoding a suitable gRNA and / or a suitable C2C9 nuclease is introduced into the chromosome of a target cell, and the nucleic acid is translated and expressed under the control of an inducible promoter, where both the encoded gRNA and C2C9 nuclease form a complex and cleave the target DNA at a position of interest. Therefore, in some embodiments, by engineering means, the bacterial genome contains a nucleic acid sequence encoding a suitable C2C9 nuclease and / or a gRNA in a plasmid, and the expression of any target gene is controlled by inducing the expression of the gRNA and C2C9 nuclease under the control of an inducible promoter. In some embodiments, the C2C9 nuclease has enzymatic activity and modifies the target DNA by means other than introducing a double-strand break. The enzymatic activity may be that possessed by C2C9 itself or may be obtained by fusing a heterologous polypeptide having an enzymatic activity to C2C9 nuclease to form a chimeric C2C9 nuclease, and the enzymatic activity may include, but is not limited to, methyltransferase activity, deamination activity, dismutase activity, alkylation activity, demethylase activity, DNA repair activity, transposase activity, recombinase activity, DNA damage activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, and the like. In the present invention, the genetic modification of a target gene at any position in the target gene can be controlled by genetic engineering to include a desired complementary nucleic acid sequence in the gene target region (e.g., DNA-target region) of the gRNA. In the present invention, the genetic modification of a target nucleic acid at any position in the target gene can be controlled by genetic engineering to include a desired complementary nucleic acid sequence in C2C9. In one embodiment, the genetic modification of a target nucleic acid at any desired position in a bacterial target DNA is used for deliberate and controlled damage of DNA.In one embodiment, it is used for the specific and controlled repair of DNA sequences at any desired location in bacterial target DNA.
[0148] The present invention also provides a method for targeting, editing, modifying or manipulating a target gene (e.g., target DNA) in a cell or in a living body, in an in vitro cell or a cell-free system, the method comprising introducing the above-mentioned C2C9 nuclease or a polynucleotide encoding it, gRNA or a polynucleotide encoding it, a recombinant expression vector, a system, a composition, a kit, etc. into a living body, in vitro cell or a cell-free system, and targeting, editing, modifying or manipulating the target gene.
[0149] In one embodiment, the method includes: (a) introducing the C2C9 nuclease or a nucleic acid encoding the C2C9 nuclease into a body, an in vitro cell, or a cell-free system; and (b) introducing the gRNA (sgRNA) or a nucleic acid (e.g., DNA) suitable for generating such a sgRNA in situ; and (c) contacting a cell or a target gene with a C2C9 nuclease or a nucleic acid encoding a C2C9 nuclease, a gRNA (sgRNA) or a nucleic acid suitable for generating such a sgRNA in situ, thereby causing one or more cleavages, cuts or edits in the target gene, wherein the C2C9 nuclease is guided to the target gene by a gRNA in a processed or unprocessed form.
[0150] In some embodiments, the target gene is a target DNA. In some embodiments, the target DNA may be naked DNA in vitro that is not bound to DNA-associated proteins. In some embodiments, the target DNA is chromosomal DNA in an in vitro cell. In some embodiments, the target gene is a target RNA. In some embodiments, the target DNA is contacted with a targeting complex comprising the C2C9 nuclease and a gRNA, and the gRNA binds to the target DNA. The inclusion of complementary nucleotide sequences provides target specificity to the targeting complex, and C2C9 nuclease provides site-specific activity. In some embodiments, the targeting complex modifies the target DNA, leading to, for example, DNA cleavage, DNA methylation, DNA damage, DNA repair, etc. In some embodiments, the targeting complex modifies the target DNA-associated polypeptide (e.g., histones, DNA-binding proteins, etc.), leading to, for example, target DNA-associated polypeptide-histone methylation, histone acetylation, histone ubiquitination, etc.
[0151] In the methods described herein, when used in vivo, the C2C9 nuclease or a polynucleotide encoding it, the gRNA or a polynucleotide encoding it, a recombinant expression vector, a system, a composition and / or a donor polynucleotide are administered directly to an individual.
[0152] In the method according to the present invention, a nucleic acid of a nucleotide sequence encoding a C2C9 nuclease or a polynucleotide of a C2C9 nuclease can be introduced into a cell by known methods. Similarly, a nucleic acid comprising a gRNA or a nucleotide sequence encoding a gRNA can be introduced into a cell by known methods. Known methods include DEAE-dextran-mediated transfection, liposome-mediated transfection, virus or phage infection, lipofection, transfection, conjugation, protoplast fusion, polyethylenimine-mediated transfection, electroporation, calcium phosphate precipitation, gene gun, calcium phosphate precipitation, microinjection, nanoparticle-mediated nucleic acid delivery, etc. For example, the plasmid is delivered by electroporation, calcium chloride transfection, microinjection, lipofection, etc. For delivery by a viral vector, the cell is contacted with a viral particle comprising a nucleic acid encoding a gRNA and / or a C2C9 nuclease and / or a chimeric C2C9 nuclease and / or a donor polynucleotide.
[0153] In one embodiment, the methods described herein involve a nuclease cleaving a target DNA in a cell, thereby creating a double-stranded break, which the cell typically repairs by: non-homologous end joining (NHEJ) and homology-directed repair.
[0154] In non-homologous end joining, double strand breaks are repaired by joining the broken ends together in situ. The process may involve inserting or deleting a small number of base pairs at the break site. Thus, the cleavage of C2C9 nuclease into DNA can be used to remove nucleic acid material from a target DNA sequence by cleaving the target DNA sequence and allowing the cell to repair the sequence without the need for an exogenous donor polynucleotide. Thus, the method can be used to knock out genes or knock in genetic material into selected loci in the target DNA.
[0155] In homology directed repair, a donor polynucleotide with homology to the cleaved target DNA sequence is used to repair the template of the cleaved target DNA sequence, thereby transferring genetic information from the donor polynucleotide to the target DNA. Thus, new nucleic acid material can be inserted / replicated at the site. In some embodiments, the target DNA is contacted with the donor polynucleotide. In some embodiments, the donor polynucleotide is introduced into a cell. Modifications to the target DNA by NHEJ and / or homology directed repair can result in, for example, gene correction, gene replacement, gene insertion, nucleotide deletion, nucleotide insertion, gene disruption, gene mutation, sequence replacement, etc.
[0156] In some embodiments, the cell containing the target gene is in vitro. In some embodiments, the cell containing the target gene is in vivo. Suitable nucleic acids comprising a nucleotide sequence encoding the C2C9 nuclease include expression vectors, where the expression vector comprising a nucleotide sequence encoding the gRNA and / or C2C9 nuclease is a recombinant expression vector. In one embodiment, the method comprises introducing the C2C9 nuclease and one or more gRNAs (gRNAs) into a cell by the same or different recombinant vectors, and contacting the cell with the vector comprising a polynucleotide encoding the gRNA and / or C2C9 nuclease, thereby allowing the vector to be absorbed by the cell.
[0157] The above methods of the invention can also be used to edit or modify DNA at multiple locations in a cell.
[0158] The above-described methods of the present invention can also be used to regulate transcription of a target DNA.
[0159] In one embodiment, the method provided by the present invention comprises ligating the complete C2C9 nuclease or a part or a completely defective one thereof, or a gRNA portion to a dimeric FOK1 nuclease to guide one or more specific DNA target sites by one or more crRNA molecules to guide endonucleolytic cleavage. In another embodiment, the method provided by the present invention comprises introducing C2C9 nuclease ligated to a dimeric FOK1 nuclease into a cell together with gRNAs under the control of a promoter, encoded as two or more RNAs or DNA that enter the cell, each gRNA comprising a repeat spacer array, wherein the spacer comprises a nucleic acid sequence complementary to a target sequence in the DNA, and the repeat sequence comprises a stem-loop structure. In one embodiment, the method provided by the present invention comprises ligating the complete C2C9 nuclease or a part or a completely defective one thereof, or a gRNA to a donor template of donor single-stranded or double-stranded DNA to guide one or more specific DNA target sites by one or more gRNA molecules to promote homologous recombination of an exogenous DNA sequence.
[0160] The present invention also provides a method for target gene-associated polypeptides, comprising contacting a target gene with a targeting complex, said targeting complex comprising the aforementioned C2C9 nuclease or a nucleic acid encoding the C2C9 nuclease, as well as a gRNA or a nucleic acid suitable for generating such an sgRNA in situ.
[0161] In some embodiments, the target gene-associated polypeptide is a histone, a DNA-binding protein, etc. In some embodiments, the targeting complex modifies the target DNA-associated polypeptide, e.g., leading to the target DNA-associated polypeptide, e.g., histone methylation, histone acetylation, histone ubiquitination, etc.
[0162] In some embodiments, the target gene is a target DNA. In some embodiments, the target DNA is a chromosomal DNA in an in vitro cell. In some embodiments, the target DNA is a chromosomal DNA in an in vivo cell, etc. In some embodiments, the target gene is a target RNA. In some embodiments, the target DNA is contacted with a target complex comprising the C2C9 nuclease and a gRNA, and the gRNA and the C2C9 nuclease form a complex, and the gRNA comprises a nucleotide sequence complementary to the target DNA, thereby providing target specificity to the target complex, and the C2C9 nuclease provides site-specific activity. In some embodiments, the CRISPR / C2C9 system based on the C2C9 nuclease uses modified polynucleotides to introduce modifications into the DNA or RNA encoding the C2C9 nuclease and / or the gRNA in a cell to edit any one or more genomic loci.
[0163] The present invention also provides cells obtained by genetically modifying a host cell with the above-mentioned C2C9 nuclease or a polynucleotide encoding it, gRNA or a polynucleotide encoding it, a recombinant expression vector, a system, or a composition.
[0164] In the present invention, the effective dosage of gRNA and / or C2C9 nuclease and / or recombinant expression vector and / or donor polynucleotide is conventional for those skilled in the art and can be determined according to different administration routes and characteristics of the disease to be treated.
[0165] C2C9 nuclease is a novel nuclease suitable for CRISPR gene editing system discovered by the applicant, which can precisely localize to the target gene when guided by the corresponding guide RNA, cleave genomic DNA, and realize double-strand break of genomic DNA. Variants of C2C9 nuclease may have different or advantageous characteristics. These C2C9 nucleases and their variants provide unprecedented alternative possibilities for genome editing. C2C9 nucleases and their variants may have different activities depending on the system they are used in. Although C2C9 has a molecular weight of half or less than Cas9 and Cas12a, C2C9 has genome cleavage efficiency close to or similar to Cas9 and Cas12a, and can realize efficient genome editing in prokaryotic bacteria and eukaryotic cells, so it has a wide range of potential applications in fields such as biotechnology and gene therapy.
[0166] The C2C9 nuclease provided by the present invention can exhibit advantageous properties over previously reported CRISPR-Cas endonucleases, such as higher activity in prokaryotic, eukaryotic and / or in vitro environments. In some embodiments, C2C9 combines one or more of the following: small size, high editing activity, and only a short PAM sequence is required. In the present invention, the small size of an RNA-guided nuclease refers to a nuclease that is about 800 amino acids or less in length.
[0167] In the present invention, the bacteria or prokaryotic bacteria are selected from Escherichia coli, Klebsiella pneumoniae, Bacteroides ovatus, Campylobacter jejuni, Staphylococcus saprophyticus, Enterococcus faecalis, Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bacteroides uniformis, Lactobacillus casei, Bacteroides fragilis, Acinetobacter ruvofii, and the like. lwoffii, Fusobacterium nucleatum, Parabacteroides johnsonii, Bacteroides oleiciplenus, Lactobacillus rhamnosus, Bacteroides massiliensis, Parabacteroides merdae, Fusobacterium mortiferum, and Bifidobacterium breve.
[0168] In the present invention, the eukaryotic cells include eukaryotic cells such as mammalian cells and fungi. The fungi include, but are not limited to, yeast and Aspergillus, such as Saccharomyces cerevisiae, Hansenula polymorpha, Pichia pastoris, Kluyveromyces fragilis, Kluyveromyces lactis, and Schizosaccharomyces pombe, Candida albicans, Candida dubliniensis, Candida glabrata, Candida guiliermondii, Candida kefyr, Candida krusei, Candida krusei, Candida lusitaniae, Candida melinii, Candida oleophila, Candida parapsilosis, Candida tropicalis and Candida utilis, Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus clavatus, Aspergillus glaucus group, Aspergillus nidulans, Aspergillus oryzae oryzae, Aspergillus terreus, Aspergillus ustus and Aspergillus versicolor.
[0169] In the embodiment of the present invention, a novel genome editing method based on the ultra-small CRISPR-C2C9 nuclease is disclosed. In the present invention, it is shown that, by using the guide and localization functions of guide RNA, C2C9 can precisely cut genomic DNA and realize double-strand breaks in genomic DNA. By utilizing the host cell's own or foreign repair mechanism, the system can efficiently and precisely realize genome editing in living cells. EXAMPLES
[0170] Hereinafter, the embodiments of the present invention will be described clearly and completely with reference to the following examples. However, of course, the described examples are merely some examples for illustrating the present invention and are not intended to limit the scope of the present invention. In the examples, those for which no specific conditions are described were carried out under normal conditions or conditions recommended by the manufacturer. If the manufacturer of the reagent or equipment used is not specified, it is assumed that they are normal products that can be purchased commercially.
[0171] The biological materials used in each example are from the following sources: Klebsiella pneumoniae NCTC9633 strain (purchased from ATCC, USA, catalog number: 13883); susceptible Escherichia coli DH5α strain (purchased from Jingsu Cowin Biotech Co., Ltd., catalog number: CW0808S). The LB liquid medium used in each example was purchased from Sangon Biotech (Shanghai) Co., Ltd., catalog number: A507002-0250; the LB solid medium was purchased from Sangon Purchased from Biotech (Shanghai) Co., Ltd., catalog number: A507003-0250; apramycin purchased from BioVision, USA, catalog number: B1521-1G; kanamycin purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., catalog number: K103024-5g. Example 1: Identification of the Protospacer Adjacent Motif (PAM) of AcC2C9 Construction of Plasmids p15a-AcC2C9Control and p15a-AcC2C9PAM
[0172] (1.1) The sequence of p15a-AcC2C9Control plasmid is SEQ ID NO: 124, and its specific construction method is as follows: The DNA sequence of AcC2C9 nuclease and its corresponding guide RNA expression cassette (the sequence is SEQ ID NO:125) and the backbone of p15a plasmid (the sequence is SEQ ID NO:126) were synthesized by Sangon Biotech (Shanghai) Co., Ltd. The two DNA fragments were assembled into p15a-AcC2C9Control plasmid by Gibson assembly technology. The sensitive cells of E. coli DH5α were transformed and screened by plating on LB medium plate containing 75μg / mL apramycin. A single clone was picked and expanded, the plasmid was extracted, and the plasmid sequence was identified by sequencing, and then the p15a-AcC2C9Control plasmid was obtained.
[0173] (1.2) The sequence of p15a-AcC2C9PAM plasmid is SEQ ID NO: 127, and its specific construction method is as follows: The following two primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd.
[0174] PAMprimerF: 5'-atcgTGTCCTCTTCCTCTTTAGCG-3' (SEQ ID NO: 128)
[0175] PAMprimerR: 5'-ggccCGCTAAAGAGGAAGAGGACA-3' (SEQ ID NO: 129)
[0176] The above two primers were annealed, and the specific reaction system was 5μl 10×T4 DNA ligase buffer (NEB), 10μL PAM primerF (10μM), 10μL PAM primerR (10μM), and 25μL ddH2O. After heating at 95℃ for 5 minutes, the temperature was slowly lowered to room temperature within 1 to 2 hours, and the two single-stranded primers were base-paired to form double-stranded DNA. The product obtained was then diluted 20 times with ddH2O.
[0177] The double-stranded DNA obtained above was inserted into the BsaI site of p15a-AcC2C9Control plasmid by Golden Gate technology. The specific reaction system was 1μL 10×T4 DNA ligase buffer, 1μL of the above 20-fold diluted phosphorylated double-stranded DNA, 20fmol p15a-AcC2C9Control plasmid, 0.5μL T4 DNA ligase (400units / μL), 0.5μL BsaI-HF (20units / μL), and finally an appropriate amount of ddH2O was added so that the total volume became 10μL. The buffer and enzymes used in the reaction were all manufactured by NEB. The reaction was carried out in a PCR machine, and the cycles were 37℃ for 2min; 16℃ for 5min, totaling 25 cycles; and 80℃ for 15min.
[0178] The 10 μL reaction mixture was transformed into a sensitive strain of E. coli DH5α and plated on a LB solid culture plate containing 75 μg / mL apramycin. Once the transformation solution was absorbed into the solid culture plate, it was cultured upside down in a 37°C incubator overnight. The transformed strains grown in the medium were transferred for storage, and the plasmids were extracted and submitted to Sangon Biotech. (Shanghai) Co., Ltd. for sequencing verification, and finally the p15a-AcC2C9PAM plasmid was obtained. Example 2: Construction of substrate plasmid pUC19-6N-library for PAM identification
[0179] The sequence of the pUC19-6N-library plasmid is SEQ ID NO: 130, and its specific construction method is as follows: Using the commercial pUC19 plasmid as a template, circular polymerase extension cloning was performed with primer 6N-F with 6N random sequence (its sequence is SEQ ID NO:131) and normal primer 6N-R (its sequence is SEQ ID NO:132). The PCR product was digested with DpnI, transformed into responsive cells of commercial E. coli DH5α, and spread on a carbenicillin-containing LBA plate. More than 100,000 single clones were scraped and collected with a spreader, mixed, and the plasmid was extracted to obtain the PAM identification substrate plasmid pUC19-6N-library. Example 3 PAM identification of AcC2C9
[0180] The p15a-AcC2C9Control plasmid constructed in Example 1 was used to transform the susceptible cells of Escherichia coli DH5α commercial strain, and then the transformant was plated on a LB solid plate containing 75 μg / mL apramycin. The next day, a single clone was picked and cultured in 100 mL of fresh LB liquid medium to reach an OD 600 When the NA ratio reached 0.5, the bacteria were harvested, washed twice with pre-chilled 10% v / v sterile glycerol on ice, and finally resuspended in 1 mL of sterile 10% v / v glycerol solution to obtain DH5α-sensitive cells carrying the p15a-AcC2C9Control plasmid.
[0181] DH5α sensitive cells carrying the p15a-AcC2C9PAM plasmid constructed in Example 1 were produced, and the production process was the same as the production process of the DH5α sensitive cells carrying the p15a-AcC2C9Control plasmid described above.
[0182] 100ng of pUC19-6N-library plasmid constructed in Example 2 was taken and introduced into DH5α sensitive cells carrying p15a-AcC2C9Control plasmid by electroporation, and then spread onto LB solid plate containing 50μg / mL carbenicillin and 75μg / mL apramycin. More than 100,000 single clones were scraped and collected by applicator, mixed, and plasmid was extracted to obtain the control library.
[0183] 100 ng of the pUC19-6N-library plasmid constructed in Example 2 was taken and introduced into DH5α responsive cells carrying p15a-AcC2C9PAM plasmid by electroporation to prepare the AcC2C9 PAM depletion library, the preparation process of which was the same as that of the control library.
[0184] The control library and PAM depletion library were used as templates, primers PAM-1F (the sequence is SEQ ID NO: 133) and PAM-1R (the sequence is SEQ ID NO: 134) were used to perform the first round of PCR, and the product was detected by electrophoresis. The second round of PCR was performed using 1 μL of the first round PCR product as a template, primers PAM-2F (the sequence is SEQ ID NO: 135) and PAM-2R (the sequence is SEQ ID NO: 136), and the product was detected by electrophoresis. The products were purified with VAHTS DNA Clean Beads magnetic beads (Vazyme Biotech Co., Ltd.). High-throughput sequencing was performed on the Illumina Hiseq2500 platform, and 1 Gb of original data was obtained, and 6N random sequence information was extracted, and the frequency of the sequence in the PAM depletion library was compared with the frequency of the sequence in the control library, and a weblog was constructed to obtain PAM information of AcC2C9 preferences.
[0185] Figure 1 shows the flow and results of the identification of PAM of AcC2C9. The results showed that AcC2C9 can efficiently recognize 5'-AAN type PAM sequences and a small amount of 5'-GAN sequences (where N is a degenerate base, representing any one of A, T, C or G). Here, the horizontal coordinates -1, -2, -3, -4, -5, and -6 represent the 1st, 2nd, 3rd, 4th, 5th, and 6th DNA bases located upstream of the 5' end of the sequence of the target DNA region in the NTS strand (non-target strand), respectively. The alphabets above them represent the preference of AcC2C9 nuclease for the DNA sequence, and the higher the ratio of the alphabet, the stronger the preference of AcC2C9 for the base. Example 4 PAM identification of CgC2C9, RdC2C9 and MiC2C9
[0186] The process of PAM identification for CgC2C9, RdC2C9 and MliC2C9 is similar to that for AcC2C9.
[0187] The DNA sequences of CgC2C9, RdC2C9 and MliC2C9 nucleases and their corresponding guide RNA expression cassettes (the sequences are SEQ ID NO:137-139) were synthesized by Sangon Biotech (Shanghai) Co., Ltd. The three nuclease DNA fragments were assembled into p15a plasmid backbone (the sequence is SEQ ID NO:126) and p15a-CgC2C9Control (the sequence is SEQ ID NO:140), p15a-RdC2C9Control (the sequence is SEQ ID NO:141) and p15a-MiC2C9Control (the sequence is SEQ ID NO:142) by Gibson assembly technology. The sensitive cells of E. coli DH5α were transformed and screened by plating on LB medium plates containing 75 μg / mL apramycin. Single clones were picked and expanded, and the plasmids were extracted and the sequences of the plasmids were identified by sequencing.
[0188] We requested Sangon Biotech (Shanghai) Co., Ltd. to synthesize the following primers.
[0189] CgPAMprimerF: 5'-tcccTGTCCTCTTCCTCTTTAGCG-3' (SEQ ID NO: 143)
[0190] RdPAMprimerF: 5'-ttccTGTCCTCTTCCTCTTTAGCG-3' (SEQ ID NO: 144)
[0191] MiPAMprimerF: 5'-gcctTGTCCTCTTCCTCTTTAGCG-3' (SEQ ID NO: 145)
[0192] The primers corresponding to CgC2C9, RdC2C9 and MliC2C9 were annealed with PAMprimerR: 5'-ggccCGCTAAAGAGGAAGAGGACA-3' (SEQ ID NO: 129), respectively. The specific reaction system was 5 μl 10×T4 DNA The mixture consisted of ligase buffer (NEB), 10 μL primerF (10 μM), 10 μL primerR (10 μM), and 25 μL ddH2O. After heating at 95°C for 5 min, the temperature was slowly lowered to room temperature within 1 to 2 hours, and the two single-stranded primers were allowed to form double-stranded DNA by base pairing. The product obtained was then diluted 20 times with ddH2O. The double-stranded DNA obtained above was inserted into the BsaI site of p15a-CgC2C9Control, p15a-RdC2C9Control, and p15a-MiC2C9Control plasmids using Golden Gate technology. The specific reaction system was 1 μL 10x T4 DNA ligase buffer, 1μL of the above 20-fold diluted phosphorylated double-stranded DNA, 20fmol of plasmid, 0.5μL of T4 DNA ligase (400units) s / μL), 0.5μBsaI-HF (20 units / μL), and finally, an appropriate amount of ddH2O was added to make the total volume 10μL. The buffers and enzymes used in the reaction were all from NEB. The reaction was carried out in a PCR machine with cycles of 37℃ for 2 min, 16℃ for 5 min, totaling 25 cycles, and then 80℃ for 15 min. The 10μL reaction mixture was transformed into a sensitive DH5α strain of E. coli and plated on LB solid culture plates containing 75μg / mL apramycin. After the transformation solution was absorbed into the solid culture plate, it was grown upside down in a 37℃ incubator overnight. The transformed strains grown in the medium were transferred and stored, and at the same time, the plasmids were extracted and sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing verification, and finally p15a-CgC2C9PAM (the sequence of which is SEQ ID NO: 146), p15a-RdC2C9PAM (the sequence of which is SEQ ID NO: 147), and p15a-MiC2C9PAM (the sequence of which is SEQ ID NO: 148) plasmids were obtained.
[0193] The PAM preferences of CgC2C9, RdC2C9 and MiC2C9 were identified. The procedure was completely similar to the PAM identification procedure of AcC2C9 in Example 3.
[0194] Figure 2 shows the results of PAM identification for CgC2C9, RdC2C9 and MiC2C9. The results showed that CgC2C9 can efficiently recognize 5'-AAS type PAM sequences (where S is a degenerate base and C represents either one of the bases A or G), and RdC2C9(B) and MiC2C9(C) can efficiently recognize 5'-AAN type PAM sequences (where N is a degenerate base and A, T or C represents either one of the bases). Example 5 Construction of p15a-AcC2C9 and pSGKP-AcC2C9 plasmids for Klebsiella pneumoniae genome editing
[0195] The sequence of p15a-AcC2C9 plasmid is SEQ ID NO: 149, and its specific construction method is as follows: Using the p15a-AcC2C9Control plasmid in Example 1 as a template, the AcC2C9 nuclease gene and the p15a plasmid backbone were amplified, respectively.
[0196] 5' primer sequence AcC2C9F to amplify the AcC2C9 nuclease gene: tcatctgtgcatatagctatactgatttcgtcagactcaca (SEQ ID NO: 150)
[0197] The 3' primer sequence ACC2C9R amplifies the gene for AcC2C9 nuclease: cgccaaccagccaCCTTATTGACCTGCACCGCTATG (SEQ ID NO: 151)
[0198] 5' primer sequence p15aF to amplify the p15a plasmid backbone: CAGGTCAATAAGGtggctggttggcgtactgtt (SEQ ID NO: 152)
[0199] 3' primer sequence p15aR to amplify the p15a plasmid backbone: atcagtatagctatatgcacagatgaaaacggtgtaaaaaaga (SEQ ID NO: 153)
[0200] The AcC2C9 gene fragment and the p15a plasmid backbone were amplified using the Phanta Max Master Mix reagent from Vazyme Biotech Co., Ltd. The reaction system consisted of 25 μL 2xPhanta Max Master Mix, 1.5 μL 5' primer (10 μM), 1.5 μL 3' primer (10 μM), 0.5 μl Template DNA (100ng / μL), 1.5μL DMSO, 20μL ddH2O. After preparing the PCR reaction system, polymerase chain reaction (PCR) was performed with the following cycles: 98℃ for 2min; then 98℃ for 20s, 55℃ for 20s, 72℃ for 3min, totaling 30 cycles; and finally 72℃ for 5min. The PCR products were collected using SanPrep column-type PCR product purification kit manufactured by Sangon Biotech (Shanghai) Co., Ltd. The specific steps of PCR product purification were performed according to the kit manual.
[0201] The obtained AcC2C9 gene fragment and p15a plasmid backbone were assembled into one plasmid by Gibson Assembly. The specific reaction system was 5μL NEBuilderHiFi DNA Assembly Master Mix (NEB), 20fmol AcC2C9 gene fragment, 20fmol p15a plasmid backbone, and an appropriate amount of ddH2O was added so that the total volume was 10μL. The reaction was carried out at 50℃ for 1 hour. 10μL of the reaction mixture was transformed into a sensitive DH5α strain of E. coli and spread on an LB solid culture plate containing 75μg / mL apramycin. When the transformation solution was absorbed into the solid culture plate, it was cultured upside down in an incubator at 37℃ overnight. The transformed strain grown on the culture plate was transferred and stored, and the plasmid was extracted using a SanPrep column-type plasmid DNA miniprep kit manufactured by Sangon Biotech (Shanghai) Co., Ltd. for subsequent experiments. The specific steps of plasmid extraction were carried out according to the kit manual. At the same time, the plasmid was sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing confirmation, and finally the p15a-AcC2C9 plasmid was obtained.
[0202] The sequence of pSGKP-AcC2C9 plasmid is SEQ ID NO:154, and its specific construction method is as follows: The DNA sequence of the guide RNA expression cassette corresponding to AcC2C9 nuclease (the sequence is SEQ ID NO:155) and the backbone of pSGKP plasmid (the sequence is SEQ ID NO:156) were synthesized by Sangon Biotech (Shanghai) Co., Ltd. The two DNA fragments were assembled into pSGKP-AcC2C9 plasmid by Gibson assembly technology. The sensitive cells of E. coli DH5α were transformed and screened by plating on LB medium plate containing 50μg / mL kanamycin. A single clone was picked and expanded, the plasmid was extracted, and the plasmid sequence was identified by sequencing, and the pSGKP-AcC2C9 plasmid was obtained. Example 6 Construction of pSGKP-AcC2C9-dha plasmid targeting Klebsiella pneumoniae genome dha gene
[0203] The sequence of pSGKP-AcC2C9-dha plasmid is SEQ ID NO: 157, and its specific construction method is as follows: First, a 20-base DNA fragment (the 20 bases are called spacer, and do not include AAN) following a specific AAG sequence (the PAM sequence recognized by AcC2C9 selected in this embodiment is AAG) in the target gene of Klebsiella pneumoniae was selected, and then the spacer sequence was inserted into the p15a-AcC2C9Control plasmid constructed in Example 1. The feature of this process is that atcg must be added to the 5' end of the single-stranded DNA sequence so that the spacer fragment can be inserted into the BsaI site of the p15a-AcC2C9Control plasmid. At the same time, a reverse complementary sequence of the spacer must be synthesized and ggcc must be added to the 5' end of the reverse complementary sequence. For example, the DNA sequence (SEQ ID NO: 158) of the dha gene spacer selected in this embodiment is 5'-TGTTTGTTACCAACTGCCTG-3', and the specific sequence design of the two primers is as follows:
[0204] PAM primerF (dha-spF): 5'-atcgTGTTTGTTACCAACTGCCTG-3' (SEQ ID NO: 159)
[0205] PAM primerR (dha-spR): 5'-ggccCAGGCAGTTGGTAACAAACA-3' (SEQ ID NO: 160)
[0206] The above two primers were annealed, and the specific reaction system was 5μl 10×T4 DNA ligase buffer (NEB), 10μL PAM primerF (10μM), 10μL PAM primerR (10μM), and 25μL ddH2O. After heating at 95℃ for 5 minutes, the temperature was slowly lowered to room temperature within 1 to 2 hours, and the two single-stranded primers were base-paired to form double-stranded DNA. The product obtained was then diluted 20 times with ddH2O.
[0207] The double-stranded DNA obtained above was inserted into the BsaI site of the pSGKP-AcC2C9 plasmid constructed in Example 4 by Golden Gate technology. The specific reaction system was 1 μL 10×T4 DNA ligase buffer, 1 μL of the above 20-fold diluted phosphorylated double-stranded DNA, 20 fmol pSGKP-AcC2C9 plasmid, 0.5 μL T4 DNA ligase (400 units / μL), 0.5 μL BsaI-HF (20 units / μL), and finally an appropriate amount of ddH2O was added so that the total volume became 10 μL. The buffer and enzymes used in the reaction were all manufactured by NEB. The reaction was carried out in a PCR device, and the cycles were 37°C for 2 min; 16°C for 5 min, for a total of 25 cycles; and 80°C for 15 min.
[0208] The 10 μL reaction mixture was transformed into a sensitive strain of E. coli DH5α and plated on a LB solid culture plate containing 75 μg / mL apramycin. Once the transformation solution was absorbed into the solid culture plate, it was cultured upside down in a 37°C incubator overnight. The transformed strains grown in the medium were transferred for storage, and the plasmids were extracted and submitted to Sangon Biotech. (Shanghai) Co., Ltd. for sequencing verification, and finally the pSGKP-AcC2C9-dha plasmid was obtained. Example 7 Preparation of electroporation-sensitive cells of Klebsiella pneumoniae containing the p15a-AcC2C9 plasmid
[0209] Klebsiella pneumoniae NCTC9633 strain (purchased from ATCC, USA, catalog number: 13883) was streaked on an LB solid culture plate and cultured upside down overnight in an incubator at 37°C. One single clone colony grown on the culture plate was taken and inoculated into 3 mL of LB liquid medium, and shaken overnight at 250 rpm in a shaker at 37°C. The next day, 1 mL of the bacterial liquid was taken and inoculated into 100 mL of fresh LB liquid medium, which was then shaken in a shaker at 37°C. The OD of the bacterial liquid was 600 When the pH reached 0.3, the bacterial solution was placed on ice and cooled for 10 minutes. The bacteria were collected by centrifugation at 8000 rpm for 5 minutes at 4°C, the medium supernatant was discarded, and the bacterial precipitate at the bottom was resuspended in 20 mL of 10% (v / v) glycerin (sterilized by high pressure and pre-cooled on ice). Centrifugation was performed at the same rotation speed, the supernatant was discarded, and the bacterial precipitate at the bottom was resuspended again in 20 mL of 10% (v / v) glycerin. Centrifugation was performed again at the same rotation speed, the supernatant was discarded, and the bacterial precipitate at the bottom was resuspended in 1 mL of 10% (v / v) glycerin. The obtained electroporation-sensitive cells of the bacteria were separated and the bacterial solution was placed in EP tubes in 50 μL portions. The separated bacterial solution was first quickly frozen in liquid nitrogen and then stored in a refrigerator at -80°C. The bacteria may be resuspended by gently blowing with a pipette to mix, as this is a light operation during resuspension.
[0210] Take one freshly produced Klebsiella pneumoniae cell line that is susceptible to electroporation. After placing it on ice for 5 to 10 minutes, 1 μg of p15a-AcC2C9 plasmid prepared in Example 4 was added. After uniform mixing, it was transferred to a 1 mm electroporation cell (Bio-Rad) and electroporated at room temperature in a GenePulserXcell electroporation device (Bio-Rad). The electroporation parameters were 1800 V, 200 Ω, and 25 μF. Immediately after electroporation, 1 mL of LB liquid medium was added, mixed uniformly, transferred to a clean EP tube, and shaken in a shaker at 37 ° C for 1 to 2 hours. 100 μL of the bacterial solution was taken and spread on a LB solid culture plate containing 75 μg / mL apramycin. When the bacterial solution was absorbed into the solid culture plate, it was cultured upside down in a 37 ° C incubator overnight. One single clone colony was taken and shaken overnight at 250 rpm in a shaker at 37 ° C in 3 mL of LB liquid medium containing 75 μg / mL apramycin. The next day, 1 mL of the bacterial suspension was inoculated into 100 mL of fresh LB medium containing 75 μg / mL apramycin, and then shaken in a shaker at 37°C. 600 When the pH reached 0.2, 1 mL of 20% w / v arabinose was added to the bacterial solution, and the bacterial solution was shaken for 2 hours, after which the bacterial solution was placed on ice to cool for 10 minutes. The bacteria were collected by centrifugation at 8000 rpm for 5 minutes at 4°C, the medium supernatant was discarded, and the bacterial precipitate at the bottom was resuspended in 20 mL of 10% v / v glycerin (sterilized by high pressure and pre-cooled on ice) and washed twice. Finally, the mixture was centrifuged again at the same rotation speed, the supernatant was discarded, and the bacterial precipitate at the bottom was resuspended in 1 mL of 10% v / v glycerin. The obtained electroporation-sensitive cells of the bacteria were separated and the bacterial solution was placed in 50 μL each in an EP tube. The separated bacterial solution was first quickly frozen in liquid nitrogen and then stored in a refrigerator at -80°C. The bacteria may be resuspended by gently blowing with a pipette to mix, as this is a light operation during resuspension. Example 8. AcC2C9 system achieves efficient gene deletion in live Klebsiella pneumoniae cells
[0211] One tube of Klebsiella pneumoniae electroporation-sensitive cells containing the p15a-AcC2C9 plasmid prepared in Example 6 was taken and placed on ice for 5-10 minutes. When melted, 200 ng of the pSGKP-AcC2C9-dha plasmid prepared in Example 5 and a dha gene homologous recombination repair template (whose sequence is SEQ ID NO: 161) with a final concentration of 5 μM were added and gently mixed uniformly. The bacterial plasmid mixture mixed uniformly with a pipette was transferred to a pre-cooled 1 mm electroporation cell (Bio-Rad) and left to stand on ice for 5 min. The condensed water on the outer wall of the electroporation cell was wiped off, and electroporation was performed in a GenePulserXcell electroporation device (Bio-Rad). The electroporation parameters were 1800 V, 200 Ω, and 25 μF. Immediately after the electric shock, 1 mL of LB culture medium was added to wash out the cells after the electric shock, and the cells were transferred to a sterile EP tube and regenerated for 1 hour at 250 rpm / min in a shaker at 37°C. The bacterial solution was applied to LB solid medium containing 75 μg / mL apramycin and 50 μg / mL kanamycin, and after the bacterial solution was absorbed, the cells were cultured upside down in a 37°C incubator overnight.
[0212] The effect of editing was verified by colony PCR on the grown colonies.
[0213] 5' primer for colony PCR verification of dha gene: 5'-TCATCATTGGCATCCTGAAA-3' (SEQ ID NO: 162)
[0214] 3' primer for colony PCR verification of dha gene: 5'-TGGTCAGCCTGCTGATTAAA-3' (SEQ ID NO: 163)
[0215] Figure 3 shows the PCR results of gene knockout in living cells of Klebsiella pneumoniae by the CRISPR-AcC2C9 system. The results showed that the selected dha gene could be precisely knocked out by the CRISPR-AcC2C9 system. Example 9: Construction of AcC2C9 protein heterologous expression plasmid pET28a-sumo-AcC2C9
[0216] Using the p15a-AcC2C9Control plasmid in Example 1 as a template, the sequence of the AcC2C9 nuclease gene was amplified and used to construct pET28a-sumo-AcC2C9 plasmid (the sequence of which is SEQ ID NO: 164) expressing AcC2C9.
[0217] 5' primer sequence for amplifying AcC2C9 gene pET-AcC2C9F (5' primer): 5'-tCTTGAAGTCCTCTTTCAGGGACCCATGGTGCAGACGGAGATCCTG-3' (SEQ ID NO: 165):
[0218] 3' primer sequence for amplifying AcC2C9 gene pET-AcC2C9R (3' primer): 5'-gtcgacggagctcgaattcttaagcTTATGGAGGCGTTGCCGTTTCG-3' (SEQ ID NO: 166):
[0219] The AcC2C9 gene fragment was amplified with Phanta Max Master Mix reagent from Vazyme Biotech Co., Ltd., and the reaction system was 25 μL 2xPhanta Max Master Mix, 1.5 μL 5' primer (10 μM), 1.5 μL 3' primer (10 μM), 0.5 μL p15a-AcC2C9 plasmid (100 ng / μL) prepared in Example 4, 1.5 μL DMSO, and 20 μL ddH2O. After preparing the PCR reaction system, polymerase chain reaction (PCR) was performed with the following cycles: 98 ° C for 2 min; then 98 ° C for 20 s, 55 ° C for 20 s, 72 ° C for 1 min, for a total of 30 cycles; and finally 72 ° C for 5 min. The PCR products were collected with SanPrep column-type PCR product purification kit from Sangon Biotech (Shanghai) Co., Ltd. The specific steps for purifying the PCR product were performed according to the kit manual.
[0220] The pET28a-sumo plasmid backbone (sequence number 167) was synthesized by Sangon Biotech (Shanghai) Co., Ltd. The two AcC2C9 gene fragments were assembled into the pET28a-sumo plasmid backbone and the pET28a-sumo-AcC2C9 plasmid by Gibson assembly technology. The responsive cells of E. coli DH5α were transformed and screened by plating on LB medium plates containing 50μg / mL kanamycin. A single clone was picked and expanded, the plasmid was extracted, and the plasmid sequence was identified by sequencing, and the pET28a-sumo-AcC2C9 plasmid was obtained. Example 10: Efficient in vitro double-stranded DNA cleavage by AcC2C9
[0221] Preparation of cleavage substrate. The genome of Klebsiella pneumoniae was used as a template to amplify the cleavage substrate with a 5'FAM-labeled primer. The sequence of the 5' primer for amplifying the cleavage substrate was 5'-CCGCATATATCGCAAAACAA-3' (SEQ ID NO: 168), and the sequence of the 3' primer for amplifying the cleavage substrate was 5'-CTGGCTGTGAACAAAGTGGA-3' (SEQ ID NO: 169). The PCR products were each recovered using the SanPrep column-type PCR product purification kit manufactured by Sangon Biotech (Shanghai) Co., Ltd.
[0222] Production of AcC2C9 nuclease. The pET28a-sumo-AcC2C9 plasmid constructed in Example 8 was transformed into E. coli expression strain BL21(DE3). The next day, the transformant was inoculated into 1 L of LB medium and cultured with shaking at 37°C. OD 60 When the β-amino acid residue reached 0.6, 0.5 mL of 1 M IPTG was added to the culture, the temperature was lowered to 16°C, and the culture was continued overnight. The overnight cultured strain was collected, disrupted by ultrasonication, and purified by HisTrap Ni-NTA (GE Healthcare) chromatography column. Then, the strain was purified by HiLoad 16 / 600 Superdex 200 pg The purified protein was concentrated using an ultrafiltration tube and stored in a buffer containing 500 mM NaCl, 10 mM Tris-HCl, pH 7.5, and 1 mM DTT.
[0223] Preparation of a complete guide RNA (its sequence is SEQ ID NO: 170) targeting the cleavage substrate. The preparation of the complete guide RNA was achieved by in vitro transcription. The transcription template DNA was synthesized by Genewiz Biotech Co., Ltd., and its sequence is SEQ ID NO: 171. The complete guide RNA was transcribed from the above template using HiScribe T7 High Yield RNA Synthesis Kit (NEB). The specific steps were performed according to the kit manual. The complete guide RNA after preparation was purified by extraction with phenol / chloroform and precipitation with ethanol.
[0224] In vitro cleavage experiments were performed in 150 mM NaCl, 10 mM MgCl2, 10 mM Tris-HCl, pH=7.5, 1 mM DTT. The total volume of the reaction was 20 μL, containing 30 nM cleavage substrate, 2 μM AcC2C9, and 2 μM intact guide RNA. The reaction times were 0, 1, 2, 5, 15, and 30 min, respectively, and the reaction temperature was 37°C. After the reaction was completed, 50 mM EDTA and 2 mg / mL Protein K were added to stop the reaction. The reactions were separated on a 6% w / v TBE acrylamide gel and imaged on a Bio-Rad GELDOC gel imaging system with blue light excitation at 488 nm.
[0225] Figure 4 shows the results of cleaving the substrate DNA with AcC2C9 nuclease. The results showed that the substrate DNA was precisely cleaved into two DNA fragments by AcC2C9. Example 11: Determination of optimal reaction conditions for AcC2C9
[0226] In order to detect the optimal reaction conditions for AcC2C9, the present invention utilized in vitro cleavage experiments to detect the activity of AcC2C9 under different reaction conditions.
[0227] Cleavage substrate. As described in Example 10.
[0228] Production of AcC2C9 nuclease. As described in Example 10.
[0229] A complete guide RNA targeting the cleavage substrate, as described in Example 10. (1) Effect of temperature on AcC2C9 activity
[0230] In vitro cleavage experiments were performed in 100 mM NaCl, 10 mM MgCl2, 10 mM Tris-HCl, pH=7.5, 1 mM DTT. The total volume of the reaction system was 20 μL, containing 30 nM cleavage substrate, 2 μM AcC2C9, and 2 μM intact guide RNA. The reaction times were 0, 5, 10, 20, 40, and 60 min, respectively, and the reaction temperatures were 30°C, 34°C, 37°C, 40°C, 43°C, 46°C, and 50°C, respectively. After the reaction was completed, 50 mM EDTA and 2 mg / mL Protein K were added to stop the reaction. The reaction products were separated on a 6% w / v TBE acrylamide gel and imaged with a Bio-Rad GELDOC gel imaging system under blue light excitation at 488 nm. The cleavage efficiency of AcC2C9 was determined from the ratio of the amount of cleavage band to the total amount of DNA substrate. (2) Effect of NaCl concentration on AcC2C9 activity
[0231] The reaction buffer for the in vitro cleavage experiments was 10 mM MgCl2, 10 mM Tris-HCl, pH=7.5, 1 mM DTT, with 50 mM, 100 mM, 200 mM, 300 mM, and 500 mM NaCl, respectively. The total volume of the reaction system was 20 μL, containing 30 nM cleavage substrate, 2 μM AcC2C9, and 2 μM intact guide RNA. The reaction times were 0, 5, 10, 20, 40, and 60 min, respectively, and the reaction temperature was 37°C. After the reaction was completed, 50 mM EDTA and 2 mg / mL Protein K were added to stop the reaction. The reaction products were separated on a 6% w / v TBE acrylamide gel and imaged with a Bio-Rad GELDOC gel imaging system under blue light excitation at 488 nm. The cleavage efficiency of AcC2C9 was determined from the ratio of the amount of cleavage band to the total amount of DNA substrate. (3) Effect of MgCl2 concentration on AcC2C9 activity
[0232] The reaction buffer for the in vitro cleavage experiments was 100 mM NaCl, 10 mM Tris-HCl, pH=7.5, 1 mM DTT, with 0 mM, 1 mM, 2 mM, 5 mM, 10 mM, and 20 mM MgCl2, respectively. The total volume of the reaction system was 20 μL, containing 30 nM cleavage substrate, 2 μM AcC2C9, and 2 μM intact guide RNA. The reaction times were 0, 5, 10, 20, 40, and 60 min, respectively, and the reaction temperature was 37°C. After the reaction was completed, 50 mM EDTA and 2 mg / mL Protein K were added to stop the reaction. The reaction products were separated on a 6% w / v TBE acrylamide gel and imaged with a Bio-Rad GELDOC gel imaging system under blue light excitation at 488 nm. The cleavage efficiency of AcC2C9 was determined from the ratio of the amount of cleavage band to the total amount of DNA substrate. (4) Effect of different divalent ions on AcC2C9 activity
[0233] The reaction buffer for the in vitro cleavage experiment was 100 mM NaCl, 10 mM Tris-HCl, pH=7.5, 1 mM DTT, containing 10 mM MgCl2, CdCl2, CoCl2, MnCl2 and NiCl2, respectively. The total volume of the reaction system was 20 μL, containing 30 nM cleavage substrate, 2 μM AcC2C9 and 2 μM intact guide RNA. The reaction times were 0, 5, 10, 20, 40 and 60 min, respectively, and the reaction temperature was 37°C. After the reaction was completed, 50 mM EDTA and 2 mg / mL Protein K were added to stop the reaction. The reaction products were separated on a 6% w / v TBE acrylamide gel and imaged with a Bio-Rad GELDOC gel imaging system under blue light excitation at 488 nm. The cleavage efficiency of AcC2C9 was determined from the ratio of the amount of cleavage band to the total amount of DNA substrate.
[0234] Figure 5 shows the reaction activity of AcC2C9 nuclease under different temperatures (A), different NaCl concentrations (B), different MgCl2 concentrations (C) and different divalent ions (D). The results show that AcC2C9 has the highest activity under the conditions of 40°C, 100 mM NaCl and 10 mM MgCl2. After 40 minutes of reaction, AcC2C9 had a cleavage efficiency of 98.8% at 40°C, 98.7% at 100 mM NaCl and 98.9% at 10 mM MgCl2. Example 12 Detection of activity after separating complete guide RNA into tracrRNA and crRNA
[0235] The complete guide RNA targeting the cleavage substrate includes tracrRNA and crRNA (an RNA sequence consisting of a DNA-target region that hybridizes with the target sequence and a tracr mate sequence). In order to verify the presence or absence of biological activity after the complete guide RNA is divided into tracrRNA and crRNA, the present invention performed an in vitro double-stranded DNA cleavage experiment.
[0236] The substrate was cleaved as described in Example 10.
[0237] The AcC2C9 nuclease was produced as described in Example 10.
[0238] Production of tracrRNA (SEQ ID NO: 172). The production of tracrRNA was achieved by in vitro transcription, and the transcription template DNA was synthesized by Genewiz Biotech Co., Ltd., and its sequence is SEQ ID NO: 173. The tracrRNA was transcribed from the above template using HiScribe T7 High Yield RNA Synthesis Kit (NEB). The specific steps were performed according to the kit manual. After production, the tracrRNA was purified by extraction with phenol / chloroform and precipitation with ethanol.
[0239] Preparation of crRNA (SEQ ID NO: 174). The preparation of crRNA was achieved by in vitro transcription, and its transcription template DNA was synthesized by Genewiz Biotech Co., Ltd., and its sequence is SEQ ID NO: 175. The transcription and purification processes of crRNA are similar to those of tracrRNA.
[0240] In vitro cleavage experiments were performed under the conditions of 150 mM NaCl, 10 mM MgCl2, 10 mM Tris-HCl, pH=7.5, 1 mM DTT. The total volume of the reaction system was 20 μL, containing 30 nM cleavage substrate, 2 μM AcC2C9, 2 μM tracrRNA, and 2 μM crRNA. The reaction time was 30 min, and the reaction temperature was 37°C. After the reaction was completed, 50 mM EDTA and 2 mg / mL Protein K were added to stop the reaction. The reaction products were separated on a 6% w / v TBE acrylamide gel and imaged with a Bio-Rad GELDOC gel imaging system under blue light excitation at 488 nm. It was found that the substrate DNA was cleaved into two DNA fragments in the same way under the conditions of crRNA and tracrRNA, indicating that the intact guide RNA has the same biological activity after being separated into tracrRNA and crRNA.
[0241] Figure 6 (A) is a schematic diagram of the complete guide RNA sequence of AcC2C9, and (B) shows the results of cleavage of substrate DNA by AcC2C9 nuclease under tracrRNA and crRNA conditions. Example 13: Identification of the cleavage site of AcC2C9 double-stranded DNA
[0242] Production of complete guide RNAs targeting short fluorescently labeled synthetic DNA. As described in Example 9.
[0243] Production of AcC2C9 nuclease. As described in Example 9.
[0244] Preparation of cleavage substrates. The cleavage substrates are four kinds of 58bp fluorescently labeled synthetic DNA sequences. Two base pair complementary primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd., and their sequences are 5'-GGCTGTGAGAAAGCGGTTCAGGTGAAAGTGAAAACACTGCCCGACGCCCAGTTCGAAG-3' (SEQ ID NO: 176) and 5'-CTTCGAACTGGGCGTCGGGCAGTGTTTTCACTTTCACCTGAA CCGCTTTCTCACAGCC-3' (SEQ ID NO: 177), respectively. The 5' and 3' ends of the two primers were labeled with FAM fluorescent groups, respectively.
[0245] In vitro cleavage experiments were carried out under the conditions of 150 mM NaCl, 10 mM MgCl2, 10 mM Tris-HCl, pH = 7.5, and 1 mM DTT. The total volume of the reaction system was 10 μl. The reaction mixture was 10 μL, containing 20 nM cleavage substrate, 2 μM AcC2C9, and 2 μM intact guide RNA. The reaction temperature was 37 °C. The reaction time was 30 min. After the reaction was completed, 10 μL 2× carboxamide loading buffer (Sangon Biotech (Shanghai) Co., Ltd.) was added to stop the reaction. The reaction products were separated by 20% TBE-Urea-PAGE and imaged by excitation with blue light at 488 nm.
[0246] Figure 7 shows the results of cleavage of four 58-bp fluorescently labeled DNA substrates by AcC2C9 nuclease. The results showed that the main cleavage site of AcC2C9 on the target strand was 21-22 nt downstream of the 3' end of the PAM site, and the main cleavage site on the non-target strand was 15-16 nt downstream of the 3' end of the PAM site. Example 14 Mammalian Cell Gene Editing of AcC2C9 Construction of Plasmid pAcC2C9Hs
[0247] The AcC2C9 described in this Example used an AcC2C9-encoding gene optimized according to preferred human codons.
[0248] The sequence of pAcC2C9Hs plasmid is SEQ ID NO: 178, and its specific construction method is as follows: The human-derived transient expression plasmid backbone (sequence is SEQ ID NO: 179), puromycin resistance gene expression cassette sequence (sequence is SEQ ID NO: 180), AcC2C9 coding gene expression cassette sequence optimized according to human codons (sequence is SEQ ID NO: 181) and guide RNA (sequence is SEQ ID NO: 123) expression cassette corresponding to AcC2C9 in human cells (sequence is SEQ ID NO: 182) were all synthesized by Sangon Biotech (Shanghai) Co., Ltd., and the four fragments were assembled into pAcC2C9Hs plasmid by Gibson assembly technology. The sensitive cells of E. coli DH5α were transformed, spread on carbenicillin-containing LBA plate, single clones were picked and amplified, the plasmid was extracted, and identified by sequencing, and the pAcC2C9Hs plasmid was obtained. Example 15: AcC2C9 achieves efficient gene editing in living human cells
[0249] AcC2C9 nuclease was able to achieve efficient gene editing in living human cells. The gene editing effect was demonstrated using human embryonic kidney cells (HEK293) as a template.
[0250] The target spacer sequence was inserted into the pAcC2C9Hs plasmid. In this embodiment, a total of five genes, VEGFA, EMX1, HEXA, DNMT1 and FANCF in the human genome, were selected as target sequences, and one 20bp target sequence DNA was selected for each of these target sequences. The oligonucleotide sequences Guide1-F, Guide1-R, Guide2-F, Guide2-R, Guide3-F, Guide3-R, Guide4-F, Guide4-R, Guide5-F and Guide5-R (the sequences are SEQ ID NOs: 183 to 192, respectively) were synthesized. After annealing Guide1-F and Guide1-R, Guide2-F and Guide2-R, Guide3-F and Guide3-R, Guide4-F and Guide4-R, and Guide5-F and Guide5-R, respectively, the five target sequence DNAs were inserted into the pAcC2C9Hs plasmid by Golden gate assembly technology, and constructed into pAcC2C9Hs-guide1, pAcC2C9Hs-guide2, pAcC2C9Hs-guide3, pAcC2C9Hs-guide4 and pAcC2C9Hs-guide5 plasmids (the sequences are SEQ ID NOs: 193 to 197, respectively).
[0251] Transient expression plasmid-mediated gene editing in human cells. Cryopreserved HEK293 cells were regenerated. After 2 days, the HEK293 cells were subcultured into 24-well plates, and the cells in each well were The number of cells is approximately 1.5 × 10 5After 16-18 hours, the cells were transfected with 500ng pAcC2C9Hs-guide1, pAcC2C9Hs-guide2, pAcC2C9Hs-guide3, pAcC2C9Hs-guide4 and pAcC2C9Hs-guide5 plasmids, respectively, using 0.75μL of lipofectamine3000 (Invitrogen). They were then cultured for 72 hours. The attached cells were digested and genomic DNA was extracted. Gene fragments were amplified by PCR with amplification primers corresponding to the genes (Guide1-IndelF and Guide1-IndelR, Guide2-IndelF and Guide2-IndelR, Guide3-IndelF and Guide3-IndelR, Guide4-IndelF and Guide4-IndelR, Guide5-IndelF and Guide5-IndelR, whose sequences are SEQ ID NOs: 198-207, respectively). The PCR products were collected from the gel. The PCR products were annealed with NEBuffer2 (NEB). Then, T7endonuclease 1 (NEB) was added and digested at 37°C for 15 min. The reaction was stopped by adding 50 mM EDTA, and the reaction products were separated by 6% TBE-PAGE and stained with 4S Red dye (Sangon Biotech (Shanghai) Co., Ltd.) to obtain images.
[0252] Figure 8 shows the results of gene editing in human cells mediated by AcC2C9 transient expression plasmid. (A) is a TBE-PAGE gel of the Indel experiment. Among the five different gene sites selected, AcC2C9 nuclease successfully achieved efficient gene editing on VEGFA, HEXA and DNMT1 genes. (B) is a statistical result of high-throughput sequencing after editing of VEGFA gene in human cells mediated by AcC2C9 transient expression plasmid. As shown in the figure, AcC2C9 nuclease could precisely introduce insertion or deletion mutations into the target sequence. Example 16 Detection of AcC2C9 editing efficiency at multiple sites in live human cells
[0253] To verify the universality of AcC2C9 in different gene sites, 47 target sites were selected following the target sequences of VEGFA, AAVS1, PDCD1, HEXA, EMX1, TP53, DNMT1 and FANCE genes in the human genome. The sequences Guide6-F-Guide52-F (the sequences are SEQ ID NOs: 208-254, respectively) and Guide6-R-Guide52-R (the sequences are SEQ ID NOs: 255-301, respectively) were synthesized by Sangon Biotech (Shanghai) Co., Ltd.
[0254] Following the same process as in Example 15, after annealing the corresponding primers, the DNA of these 47 target sequences was inserted into the pAcC2C9Hs plasmid by Golden gate assembly technology, and the successfully constructed plasmids were transfected into HEK293 cells by lipofectamine3000 (Invitrogen) to perform gene editing. The edited cells were collected and the genome was extracted, and the edited site was amplified. The products were then sent to Jiangxi HaploX Biotechnology Co., Ltd. for high-throughput sequencing to detect the cell editing efficiency.
[0255] Figure 9 shows the gene editing efficiency of the AcC2C9 transient expression plasmid at 47 sites in HEK293T cells. The site with the highest gene editing efficiency was site 15, with an efficiency of 73.7%. Example 17 Adeno-associated virus (AAV)-mediated gene editing of AcC2C9 in live human cells
[0256] The AAV2 plasmid backbone (the sequence of which is SEQ ID NO: 302) and VEGFA, AcC2C9 expression cassettes targeting AAVS1 and PDCD1 genes (their sequences are SEQ ID NO:303-305, respectively) were synthesized in their entirety. The AAV2 plasmid backbone was assembled with the three AcC2C9 expression cassettes by Gibson assembly technology to obtain AAV2-AcVEGFA (their sequence is SEQ ID NO:306), AAV-AcAAVS1 (their sequence is SEQ ID NO:307) and AAV2-AcPDCD1 (their sequence is SEQ ID NO:308). The susceptible cells of E. coli DH5α were transformed and screened by plating on LB medium plates containing 50 μg / mL carbenicillin. Single clones were picked and expanded, and the plasmids were extracted and the sequences of the plasmids were identified by sequencing.
[0257] The constructed plasmids were sent to Guangzhou Packgene Biotechnology Co., Ltd. for AAV production, and AAVs containing the AcC2C9 system targeting three sites were obtained. Cryopreserved HEK293T, HLEA, U-2OS, Huh-7 and HepG cells were regenerated. Human cells were passaged into 24-well plates, and the number of cells in each well was approximately 0.5 × 10 5 After 24 hours, 0.5 × 10 10 The cells were transfected with a copy number of AAV. After 72 hours of culture, the attached cells were digested and genomic DNA was extracted. After amplifying the editing site, the product was sent to Jiangxi HaploX Biotechnology Co., Ltd. for high-throughput sequencing to detect the cell editing efficiency.
[0258] FIG. 10 shows the editing efficiency of AAV expressing the AcC2C9 system at three different gene sites (VEGFA, AAVS1, PDCD1) in human cells HEK293T, HLEA, U-2OS, Huh-7, and HepG cells. The editing efficiencies of three different gene sites in human HEK293T cells expressing the AcC2C9 system were 18.2%, 39.4%, and 13.5%, respectively. The editing efficiencies of three different gene sites in human HLEA cells expressing the AcC2C9 system were 8.4%, 22.1%, and 12.2%, respectively. The editing efficiencies of three different gene sites in human U-2OS cells expressing the AcC2C9 system were 11.8%, 29.2%, and 29.8%, respectively. The editing efficiencies of three different gene sites in human Huh-7 cells expressing the AcC2C9 system were 5.1%, 11.9%, and 5.6%, respectively. The editing efficiencies of three different gene sites in human HepG cells expressing the AcC2C9 system were 3.9%, 7.4%, and 6.0%, respectively.
[0259] The above examples are only for illustrating the technical solutions of the present invention, and are not intended to limit the same. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art will appreciate that the specific embodiments of the present invention can be modified or some technical features can be equivalently substituted. As long as the invention does not exceed the spirit and scope of the concept, any changes and advantages that those skilled in the art can think of are within the scope of the technical solutions claimed for protection by the present invention.
Claims
1. Use of C2C9 nuclease as an RNA-guided endonuclease.
2. Use of C2C9 nuclease or a nucleic acid encoding said C2C9 nuclease in a gene editing system.
3. A gene editing system comprising a C2C9 nuclease and / or a nucleic acid encoding the C2C9 nuclease, and a guide RNA or a nucleic acid encoding the guide RNA.
4. The C2C9 nuclease is (I) a wild-type C2C9 nuclease or a fragment thereof having RNA-guided nucleic acid binding activity; (II) A variant having at least 30% sequence homology with the amino acid sequence of (I) having RNA-guided nucleic acid binding activity; (III) The above (I) or (II), further comprising a nuclear localization signal fragment. (IV), further comprising (a) one or more modifications or mutations that cause the nucleic acid to have significantly reduced endonuclease activity compared to before the modification or mutation, or to have no endonuclease activity; and / or (b) (I) or (II) or (III) above, which comprises a polypeptide or domain having another functional activity; (V) A gene editing system as described in claim 3, characterized in that it is (I), (II), or (III) above, which has endonuclease activity.
5. The gene editing system of claim 3 or 4, characterized in that the C2C9 nuclease is 800 amino acids or less and / or has RNA-guided nucleic acid binding activity.
6. A gene editing system according to any one of claims 3 to 5, characterized in that it recognizes a PAM sequence in a target sequence and / or targets a nucleic acid fragment following the PAM sequence, the length of which is 12 to 40 bp, preferably 20 bp.
7. The gene editing system of claim 6, wherein the PAM sequence is AAN, GAN, where N is a degenerate base and represents any of the bases A, T, C, or G.
8. The C2C9 nuclease comprises, from the N-terminus to the C-terminus: The gene editing system according to any one of claims 3 to 7, characterized in that it comprises: domain 1 having an amino acid sequence shown in SEQ ID NO: 1 or a variant having at least 30% sequence identity to the amino acid sequence and having RNA-guided nucleic acid binding activity and / or endonuclease activity; and domain 2 having an amino acid sequence shown in SEQ ID NO: 2 or a variant having at least 30% sequence identity to the amino acid sequence and having RNA-guided nucleic acid binding activity and / or endonuclease activity.
9. The C2C9 nuclease has any one of the amino acid sequences shown in SEQ ID NOs: 3 to 117, or has at least 30% sequence identity with any one of the amino acid sequences shown in SEQ ID NOs: 3 to 117, and has RNA-guided nucleic acid binding activity and / or enzyme activity. A gene editing system described in any one of claims 3 to 7, characterized in that it has denuclease activity.
10. The guide RNA is (i) a gene target region capable of hybridizing to a target sequence; tracr mate sequence (ii), A tracrRNA sequence (iii), wherein the tracr mate sequence (ii) and the tracrRNA sequence (iii) hybridize to form a stem-loop structure; The gene editing system according to any one of claims 3 to 7, characterized in that the guide RNA is single-stranded and the nucleic acid target region (i) is linked to a tracr mate sequence (ii) and a tracrRNA sequence (iii) in order, or the guide RNA is double-stranded, one strand of which is linked to the gene target region (i) and a tracr mate sequence (ii) and the other strand is the tracrRNA sequence (iii).
11. (1) an expression construct for C2C9 nuclease; (2) comprising an expression construct for a complete guide RNA; The gene editing system of claim 5 or 6, characterized in that the complete guide RNA comprises a guide RNA backbone and an RNA sequence corresponding to a target sequence added to the 3' end of the guide RNA backbone, and the target sequence is a nucleic acid fragment having a length of 12 to 40 bp following a PAM sequence, preferably a nucleic acid fragment having a length of 20 bp following a PAM sequence.
12. The gene editing system of claim 10, wherein the guide RNA sequence corresponds to the C2C9 nuclease, wherein the tracr mate sequence corresponding to the Actinomadura craniellae C2C9 (SEQ ID NO: 3) is represented by SEQ ID NO: 118, the tracr RNA sequence is represented by SEQ ID NO: 119, and the guide RNA backbone sequence obtained by linking them together is represented by SEQ ID NO:
120.
13. A gene editing method, comprising contacting a target gene with the gene editing system according to any one of claims 3 to 12, thereby achieving editing of the target gene.
14. i) introducing the C2C9 nuclease or a nucleic acid encoding the C2C9 nuclease into a cell; ii) introducing the guide RNA or a nucleic acid encoding the guide RNA into a cell; iii) A gene editing method as described in claim 13, characterized in that it includes a step of generating one or more incisions in a target gene mediated by C2C9 nuclease, or targeting, editing, modifying or manipulating the target gene.
15. The gene editing method of claim 13 or 14, characterized in that the C2C9 nuclease is guided to the target gene by a guide RNA in a processed or unprocessed form.
16. The gene editing method of claim 13 or 14, characterized in that the C2C9 nuclease and guide RNA form a complex to recognize a PAM sequence in the target gene, and / or the target sequence of the gene editing system is a nucleic acid fragment having a length of 12 to 40 bp following the PAM sequence, preferably a nucleic acid fragment having a length of 20 bp following the PAM sequence.
17. Further comprising the step of introducing into the cell a donor template comprising the heterologous polynucleotide sequence. A gene editing method as described in claim 14.
18. Use of the gene editing system of any one of claims 3 to 12 or the method of any one of claims 13 to 17 in performing gene editing on a target gene and / or its associated polypeptide in the body, in an in vitro cell or in a cell-free environment, characterized in that the in vitro cell comprises a bacterial cell, an archaeal cell, a fungal cell, a protist cell, a viral cell, a plant cell and an animal cell.
19. Use of the gene editing system of any one of claims 3 to 12 or the method of any one of claims 13 to 17 in performing gene editing on a target gene and / or its associated polypeptide in a living body, in an in vitro cell or in a cell-free environment, characterized in that the gene editing is selected from the group consisting of gene truncation, gene deletion, gene insertion, point mutation, transcriptional repression, transcriptional activation, base editing and guided editing.
20. A genetically modified cell, the cell being obtained by gene editing using a gene editing system according to any one of claims 3 to 12 or a method according to any one of claims 13 to 17.
Citation Information
Patent Citations
Compositions and methods for in VIVO gene editing
WO2021034336A1
Class ii, type v crispr systems
WO2021178933A2
Plant regulatory elements and uses thereof
WO2021222032A1
